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Abstract
An integrative, biochemical, genetic, and molecular biology approach utilizing
gene manipulation, gene knock outs, plasmid based protein expression, and in vivo
protein localization of fluorescence tagged proteins was employed to determine the
function of an essential protein, Lst8, in TORC1 and TORC2 signaling and a previously
uncharacterized complex, the Far3-7-8-9-10-11 complex (Far complex) in the budding
yeast, Saccharomyces cerevisiae. Mutations in SAC7 and FAR11 suppressed lethality of
both lst8Δ and tor2-21 mutations but not TORC1 inactivation, suggesting that the
essential function of Lst8 is linked only to TORC2.

Far11, a component of a six-member complex, was found to interact with Tpd3
and Pph21, conserved components of Protein Phosphatase 2A (PP2A) via coimmunoprecipitation. Mutations in FAR11 and RTS1, which encodes a PP2A regulatory
B subunit, restore phosphorylation to the TORC2 substrate Slm1 in a tor2-21 mutant.
These data suggest that TORC2 signaling is antagonized by Far11-dependent PP2A
activity.

To characterize the assembly of the Far complex in vivo, intracellular localization
of the Far complex was examined by fluorescence microscopy. It was found that the Far

xiv

complex localizes to the endoplasmic reticulum (ER). The data show that Far9 and
Far10 are tail-anchored proteins that localize to the ER first and recruit a Far8-Far7-Far3
pre-complex. Far11 is found at the ER only when all other Far proteins are assembled at
the ER. Surprisingly, ER localization is required for the Far Complex’s role TORC2
signaling because deletion of the tail-anchor domain of Far9 results in partial bypass of
the tor2-21 mutant growth defect at 37 ˚C.

Keywords: Lst8; Far11; Yeast; protein phosphatase 2A; rapamycin; TOR signaling

xv

CHAPTER I. INTRODUCTION
1.1. Saccharomyces cerevisiae: Baker’s Yeast as a Model Organism
Saccharomyces cerevisiae or Baker’s yeast is one of the most studied eukaryotes.
From its applications in baking and brewing to its versatility as a model organism in the
laboratory, the study of this organism continues to produce valuable information
relevant to both the scientific/medical community and breweries alike. In 1996, the
entire genome, approximately 12000bp or 6000 genes was sequenced (46). The following
year, Botstein et al. estimated that 31% of all yeast gene products had mammalian
counterparts, a number which they felt was actually much greater due to the fact that
the majority of the mammalian genome had yet to be sequenced (18). This sparked the
use of Baker’s yeast as a model organism for the studies of mammalian pathways.

Yeast have the ability to exist as either diploids (2N) or haploids (1N) and can
reproduce both sexually and asexually (6). Figure 1 summarizes the yeast cell cycle.
Baker’s yeast reproduce asexually through the mitotic cell cycle, a highly regulated
process also known as budding where a small bud forms on the parent cell. Briefly,
during progression through the mitotic cell cycle, genetic information is replicated
during the S and G2 phase. Replicated DNA, organelles, and cytoplasm are then
divided amongst the parent and daughter cell and the daughter cell grows until its size
1

approximately matches the parent cell during the M phase. At the end of the M phase,
cytokinesis splits the two into separate cells and both cells enter G1 phase. Cell cycle
progression is highly regulated and many signaling pathways target cell cycle
progression by inhibiting progression from G1 to S phase to prevent cell proliferation in
response to various signaling cues.

Haploid lab strains characteristically produce one of two mating pheromones: afactor, and α-factor. a-type yeast cells produce a-factor and α-type cells produce αfactor. Each type cell has receptors for the opposite type factor such that when cells are
in the presence of mating factor of the opposite type, cell cycle progression is halted at
the G1 phase and polarized cell growth begins in the direction of the mating factor.
Polarized cell growth continues until two cells of opposite mating type are able to fuse
forming a new diploid cell (6).

The fate of diploid cells depends on nutrient availability. Under rich growth
conditions, diploid cells will continue through the mitotic cell cycle. However, under
stressful or nutrient deplete conditions diploid cells will switch to sexual reproduction
or meiosis to produce new haploid cells or spores by undergoing sporulation (6, 111).
Yeast geneticists widely take advantage of this unique versatility in ploidy to create
specific mutant cell lines by mating haploids of certain genotypes, sporulating the
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resulting diploid and selecting spores that contain the desired genotypes. This makes
yeast an invaluable tool for genetic studies of conserved pathways whereby in other
organisms necessary mutants are unobtainable. Yeast have the capacity to contain
genetic information on plasmids. The power of yeast genetics becomes apparent when
essential genes are expressed on plasmids and transformed into diploid cells
heterozygous for the essential gene. When these cells are sporulated, it is possible to
obtain a haploid strain that lacks the essential gene in the genome yet are sustained due
to the presence of the essential gene on the plasmid. These strains are then able to be
manipulated to identify mutations that allow for loss of the plasmid and by association
the essential gene.

Furthermore, the usefulness of Baker’s yeast as a single cellular model organism
parallels that of bacterial systems in that yeast cells can be grown in a matter of days,
are non-pathogenic, easily amplifiable and able to be cryogenically stored indefinitely.
These characteristics paired with its conservation of eukaryotic system make Baker’s
yeast a highly convenient model organism.

3

Figure 1. Stages of the yeast life cycle.
Schematic diagram of the haploid and diploid life cycles of budding yeast.
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1.2. The TOR Signaling Pathway
Target of rapamycin (TOR) is a phosphatidylinositol kinase-related protein
kinase (PIKK) that controls eukaryotic cell growth and proliferation in response to
nutrient conditions (40, 62, 125). TOR, first identified in yeast and subsequently in
mammalian cells, is inhibited by the complex of rapamycin, an immunosuppressant
macrolide, and the immunophilin FKBP12, a peptidylprolyl cis-trans isomerase.
Rapamycin, by inhibiting TOR, serves as an immunosuppressant, an inhibitor of
restenosis, and a potential chemotherapeutic agent for cancer treatment (99, 104, 107,
116, 125).

1.2.1 The TOR Complexes
TORs are large protein kinases (~280 kD) conserved in most, if not all, eukaryotes
(125). Fungal species may possess two TOR kinases while higher eukaryotes possess
only one. The TOR kinase consists of HEAT (Huntington, Elongation factor 3, protein
phosphatase 2A, TOR1) repeats at the amino-terminal half of the protein, a FAT (FRAP,
ATM, TTRAP) domain, an FRB (FKBP12-rapamycin binding) domain, a kinase domain,
and an FATC domain (Fig. 2). The TOR kinase exists in multi-protein complexes, which
have been purified in yeast and mammals. There exist two distinctive TOR kinase
complexes in yeast: a rapamycin-sensitive TOR Complex 1 (TORC1) (consisting of Tor1
5

or Tor2, Lst8, Kog1, and Tco89) and a rapamycin-insensitive TOR Complex 2 (TORC2)
(consisting of Tor2, Lst8, Avo1, Avo2, Avo3, and Bit61) (Fig. 2A and 2B) (81, 94, 121). Of
the two branches TORC1 has been studied the most. Both complexes are partially
conserved in mammals: mTORC1 complex contains raptor, a Kog1 ortholog; mTORC2
contains rictor and mSin1, orthologs of yeast Avo3 and Avo1, respectively. GβL, the
mammalian ortholog of yeast Lst8, exists in both mTORC1 and mTORC2 (41, 63, 64, 69,
70, 98, 130). TOR is a central controller of cell growth in yeast by sensing and
responding to changes in nutrient conditions (100). Physiological processes regulated
by TOR are also partially conserved: TORC1/mTORC1 positively regulates anabolic
processes including ribosome biogenesis and protein translation while inhibiting
catabolic processes such as autophagy; TORC2/mTORC2 is involved in the organization
of the actin cytoskeleton (Fig. 2) (11, 57, 58, 83, 84, 102, 103, 117, 125, 133).
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Figure 2. TOR Complex 1 (TORC1) and TOR Complex 2 (TORC2) of budding yeast.
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(A) TORC1 is consisted of Tor1 or Tor2, Kog1, Lst8, and Tco89. Depicted are domains
of TOR, HEAT, FAT, FRB, kinase, and FATC. Rapamycin, in complex with FKBP12 (not
shown), inhibits TOR through its binding to the FRB domain of TOR. TORC1 senses
nutrient signals and promotes anabolic processes including ribosome biogenesis,
protein translation, and nutrient transport while inhibiting catabolic processes like
autophagy, stress-responsive transcription, and glycogen synthesis.

(B) TORC2 is consisted of Tor2p, Lst8p, Avo1-3p, and Bit61p. TORC2 is involved in the
regulation of the actin cytoskeleton.
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1.2.2 TORC2 signaling and the Cell Wall Integrity Pathway
All eukaryotic cells must balance the regulation of several important pathways in
order to maintain a healthy state of growth. In yeast, one example of such is the
regulation of the Cell Wall Integrity (CWI) Pathway. Integrity of the yeast cell wall is
required for cell shape and stability as well as budding to produce daughter cells to
ensure proliferation of the cell line (26, 29) Constant remodeling of the cell enables cell
expansion during normal vegetative growth and morphology changes in response to
mating pheromone (54). Because water can freely enter cells, turgor pressure can build
in the cell. The cell wall must be rigid in some areas while pliable in others to enable the
cell to take on shapes other than perfect spheres and not rupture in hypo-osmotic
environments. For this, an internal actin cytoskeleton is utilized to direct cell wall
expansion to a particular area (32). The CWI pathway is a signaling pathway in which
signals received from a family of cell surface sensors are transmitted to a Rho1/2p
GTPase switch, comprised of the Rho GTPases, Rho1 and Rho2, the Rho GDP-GTP
exchange factors (GEF) Rom2 and Tus1, and the Rho GTPase activating protein (Rho
GAP) Sac7 (11, 57, 58, 102, 130) (Fig. 3). Activated Rho1/2 transmit this signal by
activating the Pkc1-activated mitogen-activated protein (MAP) kinase cascade (56). The
Pkc1-activated MAP cascade consists of Pkc1, Bck1, redundant Mkk1 and Mkk2, and

9

Slt2. In the current model, activated Pkc1 phosphorylates Bck1 which phosphorylates
Mkk1 and Mkk2 that in turn phosphorylate Slt2. Phosphorylated Slt2 then
phosphorylates downstream targets to activate synthesis of the cell wall (reviewed in
(43)). While the CWI Pathway has been extensively characterized there is some dispute
over whether it functions in a parallel or a linear pathway with the Target of Rapamycin
(TOR) signaling pathway.

The rapamycin-insensitive TORC2 mediates organization of the actin
cytoskeleton through activation of the same Rho1/2 GTPase switch as in the CWI
pathway. How TORC2 signals to the Rho1/2 GTPase switch is not well understood and
might involve three recently identified TORC2 substrates, Slm1/2 and Ypk2 (5, 37).
Activation of Rho1 and the Pck1-Bck1-Mkk1/2-Mpk1cell integrity pathway can restore
cell growth to tor2 mutant cells (11, 57, 58, 102). Cell wall defects, induced by treating
cells with small amounts of SDS or by mutations compromising cell wall synthesis can
also suppress a tor2 mutation possibly by activating cell wall integrity signaling via
Rho1, which requires both Rom2 and Tus1, another GEF for Rho1 (101). Therefore,
TORC2 signaling and the CWI pathway likely converge to regulate organization of the
actin cytoskeleton (Fig. 4). Apart from its role in organizing the cytoskeleton, it is not
known what other pathways this complex may regulate, and no one knows what
regulates TORC2 signaling.
10
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Figure 3. Diagram of the Cell Wall Integrity pathway.
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Slm1/2 and Ypk2.
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1.2.3 Lst8: an essential component of both TOR complexes
Lst8 is essential for cell viability in S. cerevisiae (97). It is still unknown whether
the essential function of Lst8 is linked to TORC1, TORC2, or both. In TORC2, Lst8 binds
to the C-terminal kinase domain of Tor2, independent of Avo1/2/3, and Lst8 depletion
destabilizes interaction between Tor2 and Avo2 or Avo3 (126). Lst8 is also required for
full Tor2 kinase activity in vitro and its depletion leads to defective polarization of the
actin cytoskeleton similar to tor2 mutations (81, 126). However, although overexpression of MSS4 (encoding a PI-4-P 5 kinase), RHO2, ROM2, or members of the cell
integrity pathway, PKC1, MKK1, or BCK1 suppresses both tor2 temperature-sensitive
(tor2-21) and avo1 mutations (57, 58, 81), these suppressors have been reported to be
unable to suppress an lst8 mutation (81), raising the question whether the essential
function of Lst8 is linked to TORC2. On the other hand, the role of Lst8 in TORC1 is also
largely unknown.

1.2.4 Cellular localization of the TOR complexes
Earlier studies on the localization of components of the TOR complexes led to a
variety of conclusions about the identity of membranes with which components of the
TOR complexes are associated (23, 25, 72, 94, 121). What was clear from these studies is
that TORC1 and TORC2 associate with membrane structures. Several recent reports on
13

the localization of TOR components suggest that TORC2 is predominantly found as
punctate structures at the plasma membrane while TORC1 dynamically associates with
the vacuolar membrane (3). Discrepancy of these localization data may be partly due to
dynamic associations of TORC1 and TORC2 with different membrane structures in
response to changes in nutrient conditions.

1.3 Rapamycin and its clinical applications
The namesake of TOR signaling, rapamycin, is a macrolide that was first
discovered in 1975 on the island of Rapa Nui, Easter Island. Rapamycin, pictured in
Figure 5, was originally identified as an antifungal produced by the bacterium
Streptomyces hygroscopicus mainly against Candida albicans, Microsporum gypseum and
Trichophyton granulosum (120). It was later found to have immunosuppressive and
antiproliferative properties and this is its major use today. Rapamycin acts as an
immunosuppressive agent by inhibiting the response to interleukin 2 (IL-2), preventing
activation of T and B cells (86). Once inside the cell, rapamycin binds to cytosolic
FKBP12, encoded for in yeast by the gene FPR1, which then binds to the FRB domain of
the Tor kinases in TORC1. For reasons unknown, rapamycin-FKBP12 does not inhibit
TORC2, possibly due to inability to bind to the FRB domain of the Tor kinase in this
complex (81).
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The immunosuppressant rapamycin marketed under the name Sirolimus or
Rapamune by Pfiser, has low toxicity towards kidneys due to its mechanism of action
making it useful to treat patients with kidney transplants to avoid transplant rejection.
However, since rapamycin also has antiproliferative effects, a side effect is impaired
wound healing; therefore, it is typically not administered until several weeks after
surgery (86). Another clinical use for rapamycin takes advantage of its antiproliferative
property to prevent restenosis or re-narrowing of blood vessels in patients who
received coronary stents coated with rapamycin polymer. The polymer coating allows
for slow release of the drug to prevent restenosis over time (118).

Renal transplant patients are at a high risk for developing Kaposi’s sarcomas
because treatment with immunosuppressants after surgery can weaken the immune
system that normally combat the formation of this type of tumor. Because rapamycin
inhibited the progression of dermal Kaposi’s sarcomas in patients who had renal
transplants, it is currently being investigated as an anticancer drug (112). For example,
derivatives of rapamycin such as temsirolimus and everolimus are being tested for their
effects on cancers such as glioblastoma multiforme and mantle cell lymphoma (44, 95).
Combining doxorubicin and rapamycin is also being studied in mice to treat cancers
that become resistant to chemotherapeutic drugs like doxorubicin due to increased Akt
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signaling. Rapamycin is proposed to block Akt signaling rendering these cells sensitive
to chemotherapy once again (114, 123).

Rapamycin has also shown promise in treating an array of other disorders
including autism and Alzheimer’s in a mouse model as well tuberous sclerosis complex
in clinical trials (35, 110). It is being investigated in HIV, autosomal dominant polycystic
kidney disease, and progeria, a rare aging disorder that accelerates the aging process
typically leading to an early death in patients’ teenage years (13, 31, 91). Rapamycin
treatment mimics nutrient starvation and leads to an increase in lifespan in both yeast
and mouse models however this use is not recommended for humans due to its toxicity
at high doses (55, 92). The variety of applications for rapamycin stresses the importance
of TOR signaling. Yet, much remains to be understood about this signaling pathway.
Therefore, the study of TOR signaling particularly the lesser understood TORC2
signaling branch could uncover novel therapeutic targets for the treatment of these
diseases and others yet to be linked to TOR signaling.
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Figure 5. The structure of rapamycin.
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1.4 Specific Goals
Many studies on the TOR signaling pathway have provided invaluable insights
into the regulation and function of this pathway. While TOR signaling is an extensively
studied pathway, the majority of studies done were on the TORC1 signaling branch.
Much remains unknown about the regulation and possible novel functions of the
TORC2 signaling branch. Besides Tor2, Lst8 is the only other essential component of
both TOR signaling complexes. I have addressed two questions. First, the function of
Lst8 in these two complexes is unknown and whether the essential function of Lst8 is
through its action in TORC1 or TORC2 or both remains a mystery. Solving this mystery
could provide insights into the essential function of Lst8 in TOR signaling. It is not
possible to study the effect of losing an essential gene because cells will die in the
absence of that gene product. Therefore, I addressed the following question: Are there
mutations that will allow cells to survive without Lst8? Identification of such mutants
would allow further studies to be performed on the mutants to address the first
question. Second, identification of such mutants could present novel regulators of TOR
signaling. If they exist, how do Lst8 bypass mutants enable cells to survive without
Lst8? Answering this question could greatly expand the current knowledge of this
signaling pathway and could even link pathways to TOR signaling that were not
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known to be involved before, providing possible novel therapeutic targets for
regulating this pathway in many of the associated diseases.
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CHAPTER 2.
TORC2 SIGNALING IS ANTAGONIZED BY
PROTEIN PHOSPHATASE 2A AND THE
FAR3-7-8-9-10-11 COMPLEX
2.1. Summary
The target of rapamycin (TOR) kinase, a central regulator of eukaryotic cell
growth, exists in two essential, yet distinct TOR kinase complexes in the budding yeast
Saccharomyces cerevisiae: rapamycin-sensitive TORC1 and rapamycin-insensitive TORC2.
Lst8, a component of both TOR complexes, is essential for cell viability. However, it is
unclear whether the essential function of Lst8 is linked to TORC1, TORC2, or both. To
that end, I carried out a genetic screen to isolate lst8 deletion suppressor mutants. Here I
report that mutations in SAC7 and FAR11 suppress lethality of lst8Δ and TORC2deficient (tor2-21) mutations but not TORC1 inactivation, suggesting that the essential
function of Lst8 is linked only to TORC2. More importantly, characterization of lst8Δ
bypass mutants reveals a role for Protein Phosphatase 2A (PP2A) in the regulation of
TORC2 signaling. I show that Far11, a member of the Far3-7-8-9-10-11 complex
involved in pheromone induced cell cycle arrest, interacts with Tpd3 and Pph21,
conserved components of PP2A, and deletions of components of the Far3-7-8-9-10-11
complex and PP2A rescue growth defects in lst8Δ and tor2-21 mutants. Additionally,
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loss of the regulatory B’ subunit of PP2A Rts1 or Far11 restores phosphorylation to the
TORC2 substrate Slm1 in a tor2-21 mutant. Mammalian Far11 orthologs, FAM40A/B,
exist in a complex with PP2A known as STRIPAK, suggesting conserved functional
association of PP2A and Far11. Antagonism of TORC2 signaling by PP2A-Far11
represents a novel regulatory mechanism for controlling spatial cell growth of yeast.

2.2. Introduction
The target of rapamycin (TOR) kinase is a phosphatidylinositol kinase-related
protein kinase that controls eukaryotic cell growth and proliferation in response to
nutrient conditions (62, 125, 132). The TOR kinase is inhibited by the complex of
rapamycin and Fpr1, a peptidyl-prolyl cis-trans isomerase. The TOR kinase is conserved
in eukaryotes. Unlike fungal species, which may possess two TOR kinases, higher
eukaryotes such as humans possess only one. The TOR kinase exists in multi-protein
complexes, which have been purified from many different eukaryotic systems. There
exist two distinct TOR kinase complexes. In yeast, rapamycin-sensitive TORC1 consists
of Tor1 or Tor2, Lst8, Kog1, and Tco89, and rapamycin-insensitive TORC2 consists of
Tor2, Lst8, Avo1, Avo2, Avo3, and Bit61 (81, 94, 121). Both complexes are partially
conserved in mammals: mTORC1 contains the yeast Kog1 ortholog raptor, while
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mTORC2 contains mSin1 and rictor, orthologs of yeast Avo1 and Avo3, respectively;
GβL, the ortholog of yeast Lst8, exists in both mTORC1 and mTORC2 (132).

TOR regulates cell growth by sensing and responding to changes in nutrient
conditions (100). TORC1 has an essential function involving the regulation of cell
growth that is carried out when either Tor1 or Tor2 is in the complex. Under favorable
growth conditions, TORC1 promotes cell growth by maintaining robust ribosome
biogenesis (83, 84, 133). When TORC1 is inactive, there is a dramatic down-regulation of
general protein translation, an up-regulation of autophagy, accumulation of the storage
carbohydrate glycogen, increased sorting and turnover of amino acid permeases, and
activation of stress-responsive transcription factors via nuclear translocation (125). TOR
inhibition via rapamycin treatment activates a subset of stress-responsive transcription
factors (8, 22, 25, 27, 106). Rapamycin treatment can also lead to reduced gene
expression, including those encoding ribosomal proteins (RP) (125).

TORC2 has a separate essential function that is Tor2-specific, which involves cell
cycle-dependent polarization of the actin cytoskeleton (28). TORC2 mediates the
organization of the actin cytoskeleton through the activation of a Rho1/2p GTPase
switch, comprised of the Rho GTPases, Rho1 and Rho2, the Rho GDP-GTP exchange
factor Rom2, and the Rho GTPase activating protein Sac7. Activated GTP-bound Rho1
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activates Pkc1, which activates the cell wall integrity pathway MAP kinase cascade,
Bck1-Mkk1/2-Mpk1. Activation of Rho1 and the cell wall integrity pathway restores cell
growth and actin polarization to tor2 mutant cells. sac7 mutations suppress TORC2deficiency by increasing the levels of GTP-bound Rho1. How TORC2 mediates the
organization of the actin cytoskeleton is unclear and might involve three TORC2
substrates: Slm1, Slm2 and Ypk2 (4, 5, 37, 66, 115).

Lst8 is essential for cell viability in S. cerevisiae (97). It is unknown whether the
essential function of Lst8 is linked to TORC1, TORC2, or both. In TORC2, Lst8 binds to
the C-terminal kinase domain of Tor2, independent of Avo1/2/3, and Lst8 depletion
destabilizes the interaction between Tor2 and Avo2 or Avo3 (126). Lst8 is also required
for full Tor2 kinase activity in vitro and its depletion leads to depolarized actin
cytoskeleton similar to tor2 mutations (81, 126). Overexpression of MSS4, encoding a
phosphatidylinositol-4-phosphate 5-kinase, RHO1/2, ROM2, PKC1, MKK1, or BCK1
suppresses tor2 and avo1 mutations (57, 58, 81), however, these suppressors were
reported to be unable to suppress an lst8 mutation (81). The question remains whether
the essential function of Lst8 is linked to TORC2, and the role of Lst8 in TORC1 is
largely unknown.
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Here, I provide evidence that the essential function of Lst8 is linked to TORC2,
but not TORC1. I show that components of the Far3-7-8-9-10-11 complex, which have
been implicated in pheromone-induced cell cycle arrest, vacuolar protein sorting, and
cell fitness, negatively regulate TORC2 signaling. I find that Far11 interacts with protein
phosphatase 2A and that mutations in the PP2A-Rts1 subcomplex suppress TORC2deficiency. I propose that the Far3-7-8-9-10-11 complex and PP2A-Rts1 antagonize
TORC2 signaling by promoting dephosphorylation of TORC2 substrates.

2.3. Materials and methods
2.3.1. Strains, plasmids, and growth media and growth conditions
Yeast strains and plasmids used in this study are listed in Table 2 and 3 or
Appendix Table 1 and 2, respectively. Yeast cells were grown at 30 °C or 37 °C in SD
(0.67% yeast nitrogen base plus 2% dextrose), YNBcasD (SD medium plus 1% casamino
acids), Ura Leu drop-out (SD plus CSM without uracil and leucine, Bio101), or YPD (1%
yeast extract, 2% peptone, 2% dextrose) medium as indicated in the text and in the
figure legends. For lst8Δ bypass assays, SD medium with or without 1 g/L 5-Fluroorotic
acid was used to select for growth of cells that have lost URA3 plasmids. When
necessary, amino acids, adenine, and/or uracil were added to the growth medium at
standard concentrations to cover auxotrophic requirements (2).
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2.3.2. Transposon mutagenesis
lst8Δ mutant bypass genetic screens were conducted using transposon
mutagenesis as described (77). Briefly, ade2Δ lst8Δ cells carrying plasmid pRS412-LST8
were used for transposon mutagenesis; after mutagenesis, cells were plated on YPD
medium to select for colonies which were red or sectoring indicating loss of the pRS412LST8 plasmid. Putative lst8Δ bypass mutants were confirmed to be recessive, singlegene mutations using standard yeast genetic techniques. Determination of transposon
insertion sites were carried out as described (20). Briefly, a recovery plasmid encoding
the Ampicillin-resistance gene (AmpR) and URA3 was integrated into the transposon
integration site of the leb1 and leb2 mutants by homologous recombination and
transformants were selected on uracil-dropout medium. Genomic DNA was then
isolated, digested with EcoRI and ligated with T4 DNA ligase. Ligation products were
transformed into bacteria and AmpR transformants were selected for on LB Broth
supplemented with ampicillin. Transposon integration sites were determined by
sequencing of the recovered plasmids.

2.3.3. Northern Blotting
Total cellular RNAs were isolated using hot phenol method as described (45).
Cells were grown in appropriate medium to ~OD600 0.6 and collected for isolation of
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total cellular RNA. 32P-labeled probes against RPL3, RPS6a, and ACT1 were used to
probe mRNA immobilized on nylon membranes. PhosphorImager was used to record
signals of the RNA transcripts. Experiments were repeated at least twice.

2.3.4. Cellular extract preparation, immunoblotting, and immunoprecipitation
Total cellular protein extracts were prepared by disrupting yeast cells in
extraction buffer (1.85N NaOH-7.5% β-mercaptoethanol) followed by precipitation with
trichloroacetic acid (TCA) as described (129). Phosphatase treatment of total cellular
proteins was conducted as described (79). For co-immunoprecipitation experiments,
cellular lysates were prepared in IP buffer (50 mM Tris-HCl pH 7.6, 150 mM NaCl, 0.5%
Triton X-100, and protease inhibitors). Cell extracts (~3 mg proteins) were incubated at 4
°C for 1 h with anti-myc antibody (9E10, Roche), after which 30 μl of a 50% slurry of
protein G-Sepharose (Roche) was added to each sample and the samples were further
incubated at 4 °C for 2 h. Washed immunoprecipitates bound to the sepharose beads
were released by boiling in 1X SDS-PAGE loading buffer. The released immune
complexes were analyzed by Western blotting. myc- and HA-tagged proteins were
probed with anti-myc antibody and anti-HA antibody (3F10, Roche), respectively.
Chemiluminescence images of Western blots were captured using the Bio-Rad ChemiDoc photo documentation system (Bio-Rad). Experiments were repeated at least twice.
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2.3.5. Actin staining and GFP fluorescence microscopy
The actin cytoskeleton was visualized in rhodamine phalloidin-stained,
formaldehyde-fixed cells, as described (2). Overnight cultures were diluted to ~OD 0.1
and allowed to grow at 30 °C for 2 h and then switched to 37 °C for 3 h before
formaldehyde was added to a final concentration of 3.7%. After fixing for 1 h, 1mL of
fixed cells were collected, washed in PBS buffer and stained with rhodamine phalloidin
conjugate (Invitrogen) and visualized by fluorescence microscopy. GFP fluorescence of
GFP-tagged proteins was analyzed in cells grown to log phase. Fluorescence images of
rhodamine phalloidin-labeled actin structures and GFP-tagged proteins were acquired
with a Photometrics Coolsnap fx CCD camera and Metamorph Imaging Software and
processed using ImageJ (NIH) and Adobe Photoshop. Experiments were repeated at
least twice.

2.3.6. Preparation of recombinant 6xHis-tagged Slm1
PCR-amplified SLM1 coding sequence was cloned into the SacI and XhoI sites of
pET24a vector (Novagen). The resultant plasmid was transformed into BL21(DE3)
competent cells (Novagen) and expression of 6xHis-tagged Slm1 was induced by
adding 1 mM IPTG to bacterial cultures grown at 20 °C for 16 h. Recombinant Cterminal 6xHis-tagged Slm1 was purified under native conditions using Ni-NTA
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agarose beads (Qiagen) as described in the product instruction manual. 14 mg Slm1His6 was obtained from 1 L induced culture. Experiments were repeated at least twice.

2.3.7. In vitro kinase assay of Slm1 phosphorylation by Tor2-HA
Yeast strains expressing 3xHA-tagged Tor2 were grown overnight to mid-log
phase and cellular lysates were prepared in lysis buffer (50 mM Tris-HCl, pH 7.6, 150
mM NaCl, 1% Triton X-100, and protease inhibitors) by vortexing with glass beads. Cell
extracts (~3 mg proteins) were incubated with 100 µl protein A-agarose beads (Roche) at
4 °C for 1 h to remove nonspecific binding proteins. Precleared cell lysates were then
incubated with 16 μg anti-HA antibody (12CA5, Roche) for 1 h, after which 40 µL of a
50% slurry of protein A-agarose beads was added to each sample and the samples were
further incubated at 4 °C for 1 h. Precipitates were washed twice with 1ml lysis buffer,
twice with 1ml wash buffer (50 mM Tris-HCl, pH 7.6, 300 mM NaCl, and protease
inhibitors), and once with 1ml kinase buffer (20 mM Tris-HCl pH 7.6, 50 mM NaCl, 5
mM MgCl2, 1mM PMSF). After the final wash, beads were resuspended in 25 µL of
kinase buffer plus 1 mM dithiothreitol (DTT). The reaction was initiated by adding 25
µL reaction mixture (kinase buffer with 1 mM DTT, 0.4 mM ATP, 5µCi of [γ-32P]-ATP
(PerkinElmer), 5 µg recombinant Slm1-His6). After incubation for 30 minutes at 30°C,
the reaction was terminated by adding 25ul 3x SDS gel-loading buffer (150 mM Tris-
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HCl, pH 6.8, 6% SDS, 30% glycerol, 0.3% bromophenol blue) and 8.5ul 1 M DTT and
boiling for 4 minutes. 20 µl samples were fractionated by SDS–PAGE on 7.5%
polyacrylamide gels in triplicate, with one dried for detecting 32P-incorporation in Slm1
by autoradiography (Molecular PhosphorImager FX, Bio-Rad), one stained by Coomassie
Blue for detecting 6xHis-tagged Slm1, and one processed for Western blotting for
detecting HA-Tor2. A mock treatment experiment was conducted using anti-HA
immunoprecipitates from cells expressing non-tagged Tor2. Experiments were repeated
at least twice.

2.4. Results
2.4.1. Mutations in SAC7 and FAR11 suppress lethality due to an lst8Δ mutation
To gain insights into the essential function of Lst8, I conducted a genetic screen
to search for mutations that allow cells to survive without Lst8 by employing an ade2
colony sectoring assay (Fig. 1D). This assay takes advantage of a buildup of purine
precursors in the vacuole, which results in colonies that appear red in ade2 mutant cells.
I utilized a previously constructed Tn3::lacZ::LEU2 mutagenesis library (20) to introduce
mutations in an lst8Δ ade2Δ mutant carrying plasmid pRS412-LST8 (CEN LST8 ADE2)
and screened for red or sectoring lst8Δ bypass (leb) mutant cells on YPD medium, which
had lost or were in the process of losing the pRS412-LST8 plasmid. Of approximately
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30,000 Leu+ transformants, 49 viable solid red or sectoring colonies were selected for
further analysis. Of the 49, 11 colonies were pure red. Crossing to an ade1Δ strain
resulted in non-complementation of the red phenotype in one of the 11 pure red
colonies indicating that the red phenotype was due to a mutation in ADE1 and not the
loss of the pRS412-LST8 plasmid. Whereas, crossing to an ade2Δ strain resulted in noncomplementation of the red phenotype in the remaining 10 pure red colonies indicating
that the red phenotype is due to a mutation in ADE2 or loss of the pRS412-LST8
plasmid. However, wild-type LST8 was found by PCR to be present in all 11 pure red
colonies, which were deemed false positives. The remaining 38 sectoring colonies were
analyzed similarly and the red sectoring phenotype of one was due to an ADE1
mutation while 35 were due to mutations in ADE2. PCR genotyping confirmed the
absence of pRS412-LST8 in the remaining two mutants, termed leb1 and leb2. In these
two leb mutants, the lst8Δ bypass phenotype was found to co-segregate with Leu+ after
crossing to an lst8Δ leu2 ade2Δ pRS412-LST8 strain of the opposite mating type and
tetrads were dissected, indicating that the transposon insertion had produced the
mutant phenotype. Figure 1A shows that, in contrast to wild-type cells, leb1 and leb2
mutants form both red and sectoring colonies, indicating loss of the pRS412-LST8
plasmid.
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I identified the transposon insertion site in the leb1 and leb2 mutants by plasmid
rescue and sequencing of the recovered plasmids as described by Burns et al. (1994) and
summarized in Figure 1E. The transposon insertion sites in the leb1 and leb2 mutants
were found to be in the open reading frames of SAC7 and FAR11, respectively.
Consistently, Figure 1B-C shows that wild-type SAC7 and FAR11 on a centromeric
plasmid can complement leb1 and leb2 mutations, respectively. Furthermore, a sac7Δ or
far11Δ mutation in an lst8Δ ade2Δ pRS412-LST8 strain also led to lst8Δ bypass (loss of
pRS412-LST8 is indicated by the red colony phenotype in Figure 2A).
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Figure 1. Mutations in SAC7 and FAR11 bypass lst8Δ.
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Figure 1 (cont.)
(A) Isolation of lst8Δ bypass (leb) mutants using ade2-based colony sectoring assay.
Wild-type (lst8Δ ade2Δ) (ZLY3081) and isogenic leb1 (TPY104) and leb2 (TPY103) mutant
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cells carrying a centromeric plasmid encoding ADE2 and LST8 (pZL1255) were streaked
on YPD medium.
(B) SAC7 complements a leb1 mutation. leb1 mutant cells (lst8Δ ade2Δ leb1) carrying
pRS412-LST8 and either pRS416 empty vector (Vector) or pRS416-SAC7 (SAC7,
pZL2422) were grown on YNBcasD medium supplemented with adenine.
(C) FAR11 complements a leb2 mutation. leb2 (lst8Δ ade2Δ leb2) mutant cells carrying
pRS412-LST8 and either pRS416 empty vector (Vector) or pRS416-FAR11 (FAR11,
pZL2550) were grown on YNBcasD medium supplemented with adenine.

(D) Diagram of colony sectoring assay

(E) Scheme for recovering and identifying the location of a transposon insertion within
the yeast genome. Sequence obtained can be compared to the Saccharomyces Genome
Database to identify location of insertion. Adapted from the TRIPLES database
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2.4.2. sac7Δ and far11Δ mutants are sensitive to rapamycin
Whether the essential function of Lst8 is linked to TORC1, TORC2, or both has
yet to be determined. I tested the ability of sac7Δ and far11Δ mutations to suppress
TORC1 inactivation by rapamycin treatment and TORC2-deficiency due to a
temperature-sensitive tor2-21 mutation. An fpr1Δ mutation enables cells to grow in the
presence of rapamycin, however, far11Δ lst8Δ, far11Δ (far11Δ lst8Δ pRS412-LST8), sac7Δ
lst8Δ and sac7Δ (sac7Δ lst8Δ pRS412-LST8) cells were unable to grow on YPD medium
supplemented with 200 nM rapamycin (Fig. 2A), demonstrating that these two lst8Δ
bypass mutations do not suppress a severe or complete loss of TORC1 activity.
Consistently, sac7Δ and far11Δ mutations failed to restore cell growth to tor1Δ tor2-21
double mutants grown at 37 °C, which have defects in the function of both TORC1 and
TORC2 (Appendix Fig. A1 and (102)). In contrast, sac7Δ and far11Δ mutations restored
cell growth to a tor2-21 mutant grown at 37 °C, which causes a specific defect in only
TORC2 (Fig. 3C and 4C), consistent with previous findings that sac7Δ suppresses a tor221 mutation (102). These data suggest that the essential function of Lst8 may be linked
to TORC2, but not TORC1.
It is conceivable that lst8Δ may result in a partial loss of TORC1 activity, which is
not sufficient to support cell growth but is not severe enough to prevent sac7Δ and
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far11Δ mutations from restoring partial cell growth to lst8Δ mutant cells. To test this
possibility, I tested the sensitivity of wild type, fpr1Δ, sac7Δ, and far11Δ mutant cells to
lower concentrations of rapamycin (Appendix Fig. A2). It has been reported that sac7Δ
and far11Δ mutant strains in the BY4741 background are hypersensitive to treatment
with 10 nM rapamycin (128). In the presence of <10 nM rapamycin, a far11Δ mutant in
the BY4741 background has been reported to grow better than wild-type cells (60). I
analyzed cell growth in the presence of 2-20 nM rapamycin and found that sac7Δ
resulted in hypersensitivity to rapamycin treatment. A far11Δ mutant, in contrast, grew
slightly better than wild-type cells when treated with 3 and 5 nM rapamycin. In the
presence of 7-20 nM rapamycin, however, far11Δ cells no longer grew better than wildtype cells. In my strain background, treatment of wild-type cells with 10 nM rapamycin
likely reduces TORC1 activity to just below the threshold that supports cell growth. My
observations that sac7Δ and far11Δ bypass lst8Δ but not treatment with 10 nM
rapamycin strongly suggest that the essential function of lst8 is not linked to TORC1.

To further corroborate my hypothesis that Lst8 is not essential for TORC1
activity, the effect of lst8Δ on the expression of genes encoding ribosomal proteins (RP),
which is positively regulated by TORC1, was examined. Utilizing sac7Δ to obtain a
viable lst8Δ mutant, the expression of two RP genes, RPL3 and RPS6A, encoding the L3
protein of the large (60S) ribosomal subunit and the S6 protein of the small (40S)
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ribosomal subunit, respectively, was compared in LST8 sac7Δ versus lst8Δ sac7Δ mutant
cells by Northern blot analysis. As expected, TORC1 inactivation due to rapamycin
treatment inhibited expression of both RPL3 and RPS6A (Fig. 2B). In contrast, lst8Δ only
mildly reduced the expression of RPL3 and RPS6A, suggesting that lst8Δ does not lead
to severe loss of TORC1 activity.

2.4.3. lst8Δ causes mislocalization of Bit61 and Avo3, but not Kog1
Recent research has demonstrated that the TORC1 components are located on
intracellular membranes with a concentration on the vacuolar membrane while TORC2
components appear as punctate spots at the plasma membrane (3, 10, 12, 113, 121). It
has been proposed that plasma membrane localization of TORC2 is essential for cell
viability (10). Isolation of lst8Δ mutant suppressors allowed me to examine the role of
Lst8 in the cellular localization of TOR complex components. GFP fluorescence was
analyzed in sac7Δ far11Δ double and sac7Δ far11Δ lst8Δ triple mutants expressing GFPtagged TORC1 component Kog1 and TORC2 components Bit61 and Avo3. As
previously reported, Bit61 and Avo3 localized to the plasma membrane as punctate
spots in wild-type LST8 cells (Fig. 2C) (10). An lst8Δ mutation, however, largely
abolished punctate plasma membrane localization of Bit61 and Avo3. In contrast, lst8Δ
did not affect localization of Kog1 to the vacuolar membrane (Figure 2C). These
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findings are consistent with my hypothesis that the essential function of Lst8 is linked
to TORC2, but not TORC1, and further suggest that Lst8 is required for proper cellular
localization of TORC2.
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Figure 2. TORC1 function is not grossly affected in an lst8Δ mutant.
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(A) sac7Δ and far11Δ mutations do not confer resistance to rapamycin. Wild type
(ZLY423) and isogenic mutant cells as indicated (far11Δ lst8Δ TPY115; far11Δ, TPY114;
fpr1Δ, TPY122; sac7Δ lst8Δ, ZLY2405; sac7Δ, ZLY2404) were grown on YPD medium
with or without 200 nM rapamycin. The lack of a pRS412-LST8 plasmid results in the
far11Δ lst8Δ and sac7Δ lst8Δ double mutant cells having a red phenotype.
(B) lst8Δ has little effect on the expression of RPL3 and RPS6A. Expression of RPL3,
RPS6A and ACT1 in sac7Δ mutant cells (ZLY2404) treated with drug vehicle (+Veh) or
200 nM rapamycin (+Rapa), sac7Δ single (ZLY2404) and sac7Δ lst8Δ double (ZLY2845)
mutant cells were analyzed by Northern blotting as described in Materials and
Methods.
(C) lst8Δ causes mislocalization of Bit61 and Avo3, but not Kog1. Wild-type LST8 (LST8
sac7Δ far11Δ) and lst8Δ mutant (lst8Δ sac7Δ far11Δ) cells expressing no GFP-tagged
proteins (TPY1264, TPY1266), Bit61-GFP (TPY358, TPY366), Avo3-GFP (TPY369,
TPY407), or Kog1-GFP (TPY371, TPY413) were grown in SD medium and observed by
bright field (DIC) and GFP fluorescence microscopy. GFP fluorescence images were
captured and processed using the same parameters. Arrows indicate punctate plasma
membrane localization of Bit61 and Avo3. Background signals in cells expressing no
GFP-tagged proteins, especially in the lst8Δ mutant strain, are due to autofluorescence
caused by an ade2 mutation.
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2.4.4. Mutations of the Far3-7-8-9-10-11 Complex bypass lst8Δ and tor2-21
mutations
Far11 has been shown to be involved in cell cycle arrest in response to mating
pheromone in a multi-protein complex with Far3, Far7, Far8, Far9, and Far10 (59, 68).
Interactions among these six Far proteins are based mostly on yeast two-hybrid assays
(68, 73); however, Far3 has been reported to interact with Far11 by
coimmunoprecipitation. I generated strains coexpressing HA-tagged Far11 and myctagged Far7, Far8, Far9, Far10, and Far11 under the control of their respective
endogenous promoters to test whether Far11 interacts with Far7, Far8, Far9, Far10 or
itself by coimmunoprecipitation. FAR11-HA was found to be functional by its ability to
complement a far11Δ mutation using the colony-sectoring assay described for Figure 1C
(Appendix Fig. A3). myc-tagged Far proteins are functional as described previously
(68). Far11-HA in cell lysates prepared for coimmunoprecipitation exists as two bands
on Western blots (Fig. 3A). The faster mobility form of Far11-HA is likely to be a
proteolytically truncated form of Far11 since Far11-HA exists as a single band on
Western blots when the total cellular proteins were prepared by disrupting cells in the
presence of 1.85N NaOH-7.5% β-mercaptoethanol and followed by precipitation with
trichloroacetic acid (Appendix Fig. A4). myc-tagged proteins were precipitated from
cell lysates using anti-myc antibody. Figure 3A shows that Far11-HA
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coimmunoprecipitates with myc-tagged Far7, Far8, Far9, Far10, but not Far11,
demonstrating that Far11 interacts with other Far proteins in vivo.

Since Far11 is part of a multi-protein complex, it is possible that the entire
complex is involved in TORC2 signaling. I examined whether mutations of the Far
complex bypass lst8Δ and tor2-21 as well. lst8Δ farΔ double mutants each carrying a
centromeric plasmid encoding LST8 and URA3 ([CEN URA LST8]) were grown on SD
medium without or with 5-fluoroorotic acid (5-FOA), which selects for cells that have
lost the URA3 plasmid. Based on their relative growth in the presence of 5-FOA,
mutations in FAR3, FAR7, FAR8, FAR9, FAR10, and FAR11 bypass lst8Δ to varying
degrees: far11> far8/9> far3/7> far10 (Fig. 3B). farΔ mutations were subsequently found to
suppress a tor2-21 mutation at 37 °C (Fig. 3C). The tor2-21 suppression phenotypes of
far3, far7, far8, far9, far10, and far11 mutations largely mirror that of their respective lst8Δ
bypass (Fig. 3B and C), indicating that the function of Lst8 is tightly linked to TORC2.

Far9 and Far10 are homologous proteins with 31% sequence identity and 47%
sequence similarity, yet they have different lst8Δ and tor2-21 suppression phenotypes. I
generated a tor2-21 far9Δ far10Δ triple mutant and found that its growth was only
marginally better than the tor2-21 far9Δ double mutant (Appendix Fig. A5), indicating
that of the two, Far9 plays the primary role in TORC2 signaling.
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It is unclear whether an lst8Δ or tor2-21 mutation leads to complete loss of
TORC2 activity. Deletion of TOR2, encoding the only TOR kinase in TORC2, abolishes
TORC2 activity. To test whether far11Δ bypasses tor2Δ, spores of tetrads from
FAR11/far11 TOR2/tor2Δ::kanMX4 diploid cells were assessed for viability. All tetrads
produced at most two viable spores, none of which were geneticin-resistant (kanXM4
confers geneticin resistance) (Appendix Fig. A6). Since FAR11 and TOR2 are not located
on the same chromosome, 25% of spores should have the genotype tor2Δ::kanMX4
far11Δ. Failure to obtain viable geneticin-resistant spores indicates that far11Δ is unable
to bypass tor2Δ. Similarly, I found that far11Δ failed to bypass avo1Δ or avo3Δ (Appendix
Fig. A6). Since far11Δ is able to suppress lst8Δ and tor2-21 mutations, it is likely that
lst8Δ and tor2-21 mutations do not completely abolish TORC2 activity and that far11Δ
can restore growth to cells with a severe loss, but not a total loss of TORC2 activity.
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Figure 3. Mutations in FAR3, FAR7, FAR8, FAR9, FAR10, and FAR11 bypass lst8Δ and
tor2-21 mutant phenotypes.
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(A) Far11-HA interacts with myc-tagged Far7, Far8, Far9, and Far10. Cell lysates of
strains TPY978 (Far7-myc), TPY981 (Far8-myc), TPY1001 (Far9-myc), TPY1002 (Far10myc), and TPY1003 (Far11-myc) coexpressing Far11-HA (pZL2762) were subjected to
immunoprecipitation with anti-myc antibody. HA- and myc-tagged proteins were
detected by Western blotting. * denotes a likely truncation product of Far11-HA.
(B) Mutations in FAR3, FAR7, FAR8, FAR9, FAR10, and FAR11 bypass lst8Δ. Serial
dilutions of wild-type (RBY231) and isogenic mutant cells (lst8Δ, RBY223; lst8Δ far3Δ,
MOY142; lst8Δ far7Δ, MOY145; lst8Δ far8Δ, MOY146; lst8Δ far9Δ, MOY169; lst8Δ far10Δ,
MOY149; lst8Δ far11Δ, MOY150 ) carrying a centromeric plasmid encoding URA3 and LST8
(pZL339) as indicated were grown on SD medium without or with 5-FOA.

(C) Mutations in FAR3, FAR7, FAR8, FAR9, FAR10, and FAR11 suppress tor2-21 at 37 °C.
Serial dilutions of indicated cells (WT, SH100; tor2-21, SH121; tor2-21 far3Δ, TPY157; tor2-21
far7Δ, TPY147; tor2-21 far8Δ, TPY213; tor2-21 far9Δ, TPY207; tor2-21 far10Δ, TPY151; tor2-21
far11Δ, TPY116 ) were grown on YPD medium at 30 °C and 37 °C for 3-4 days.
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2.4.5. sac7Δ and far11Δ additively suppress tor2-21
TORC2 is involved in the organization of the actin cytoskeleton. A tor2-21
mutant shows depolarization of the actin cytoskeleton and several tor2-21 suppressors
can restore actin polarization to tor2-21 mutant cells (102). I compared actin structures in
wild-type, tor2-21, tor2-21 sac7Δ, and tor2-21 far11Δ mutant cells to establish whether
actin polarization defects caused by a tor2-21 mutation could be restored by a
far11Δ mutation. As expected, a sac7Δ mutation restored polarization of the actin
cytoskeleton in tor2-21 mutant cells grown at 37 °C (Fig. 4A). Similarly, a far11Δ
mutation restored polarization of actin structures in tor2-21 mutant cells grown at 37 °C
(Fig. 4B). A recent genome-wide study of genetic interactions in yeast showed that
far11Δ restored actin polarization to tsc11-1 (avo3-1) mutant cells (7). Together, these
data establish that Far11 negatively regulates TORC2-mediated polarization of the actin
cytoskeleton.
Similar phenotypes of far11Δ and sac7Δ mutations prompted me to determine
whether they act through the same molecular mechanism. Accordingly, I compared the
growth of a tor2-21 sac7Δ far11Δ triple mutant to wild-type, tor2-21, tor2-21 sac7Δ, and
tor2-21 far11Δ mutants at 30 °C versus 37 °C. Figure 4C shows that while all strains grew
equally well at 30 °C, the tor2-21 sac7Δ far11Δ mutant grew better than either the tor2-21
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far11Δ or the tor2-21 sac7Δ mutant at 37 °C, indicating that far11Δ and sac7Δ have
additive effects in suppressing tor2-21. To examine whether sac7Δ and far11Δ have an
additive effect in suppressing an actin depolarization defect in tor2-21 mutant cells, I
determined the percentage of cells with polarized actin cytoskeleton in wild-type and
isogenic tor2-21, tor2-21 sac7Δ, tor2-21 far11Δ, tor2-21 sac7Δ far11Δ mutant cells. Table 1
shows that the effect of sac7Δ and far11Δ on the restoration of actin structure
polarization is additive. Sac7 and Rom2 have opposing roles in mediating TORC2
function and it has been proposed that Tor2 activates Rho1 via Rom2 (102). Therefore,
to determine whether tor2-21 suppression by far11Δ is Rom2-dependent, I introduced a
rom2Δ mutation into the tor2-21 far11Δ mutant. Figure 4D shows that a rom2Δ mutation
greatly reduced the tor2-21 suppression phenotype of a far11Δ mutation at 37 °C but did
not abolish it, suggesting that far11Δ suppression of TORC2-deficiency is not entirely
dependent on the Rom2-mediated Rho1/2 GTPase switch.
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Figure 4. sac7Δ and far11Δ additively suppress tor2-21.
(A-B) Mutations in SAC7 and FAR11 restore polarization of the actin cytoskeleton to
tor2-21 mutant cells grown at 37 °C. Actin structures in indicated cells (WT, SH100; tor221, SH121; tor2-21 sac7Δ, TPY110; tor2-21 far11Δ TPY116) were detected by staining with
rhodamine phalloidin as described in Materials and Methods.
(C) sac7Δ and far11Δ have an additive effect in suppressing tor2-21. Serial dilutions of
indicated cells (WT, SH100; tor2-21, SH121; tor2-21 sac7Δ, TPY110; tor2-21 far11Δ TPY311;
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tor2-21 sac7Δ far11Δ, TPY301) were grown on YPD medium at 30 °C and 37 °C for 2-3
days.
(D) far11Δ suppression of tor2-21 is partially dependent on ROM2. Serial dilutions of
indicated cells (WT, SH100; tor2-21, SH121; tor2-21 far11Δ TPY311; tor2-211 far11Δ rom2Δ,
TPY680) were grown on YPD medium at 30 °C and 37 °C.

Table 1. Quantitative analysis of polarization of the actin cytoskeleton.
Strain
Wild-type
tor2-21
tor2-21 sac7Δ
tor2-21 far11Δ
tor2-21 sac7Δ far11Δ

# cells imaged
474
424
504
461
451

# polarized cells
357
89
267
240
318
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% polarized cells
75.3%
21.0%
53.0%
52.1%
70.5%

2.4.6. Far11 interacts with Tpd3 and Pph21, components of PP2A
The data so far raise the question: How does the Far3-7-8-9-10-11 complex
mediate TORC2 signaling? The human ortholog of yeast Far11 exists in the human
STRIPAK complex, which also contains components of PP2A (48). The Far11 ortholog in
Drosophila has also been reported to interact with PP2A in the dSTRIPAK complex (96).
Therefore, I tested whether Far11 in yeast also exists in a complex with PP2A. In yeast,
the heterotrimeric PP2A phosphatase consists of the regulatory A subunit Tpd3, the
regulatory B subunit Cdc55 or B’ subunit Rts1, and one of the two homologous and
functionally redundant catalytic C subunits Pph21 or Pph22 (34). Among approximately
75 proteins that genetically or biochemically interact with Far11 in various genomewide gene/protein interaction studies (Saccharomyces Genome Database), Tpd3 has been
found to interact with Far11 by yeast two-hybrid analysis (119). The significance of this
interaction remains unknown.

To establish the interaction between Far11 and PP2A in yeast, lysates from cells
coexpressing 3x HA-tagged Far11 and 3x myc-tagged Tpd3 or Pph21 were subjected to
immunoprecipitation using anti-myc antibody. TPD3-myc and PPH21-myc constructs
were found to be functional by their ability to rescue growth defects of tpd3Δ and
pph21/22Δ mutants respectively (Appendix Fig. A7). No Far11-HA was detected in the
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IP pellet from cells expressing Far11-HA alone. In contrast, Far11-HA was recovered in
the IP pellet from cells coexpressing Tpd3-myc, and to a lesser extent, from cells
coexpressing Pph21-myc (Fig. 5A) likely because C-terminal tagging of Pph21 perturbs
methylation at its C-terminus required for PP2A complex stability (122). These findings
establish that Far11 interacts with PP2A phosphatase.

2.4.7. Defects in PP2A-Rts1 bypass lst8Δ and tor2-21 mutations
To investigate whether PP2A is involved in TORC2 signaling, I examined
whether mutations in PP2A components bypass lst8Δ. I analyzed the growth of an lst8Δ
tpd3Δ double mutant, an lst8Δ rts1Δ double mutant, an lst8Δ cdc55Δ double mutant, and
an lst8Δ pph21Δ pph22Δ triple mutant each carrying a centromeric plasmid encoding
URA3 and LST8 on SD medium without or with 5-FOA. tpd3Δ, rts1Δ, and pph21/22Δ
mutations, but not a cdc55Δ mutation, were able to bypass lst8Δ (Fig. 5B and C),
indicated by their ability or inability to grow in the presence of 5-FOA, suggesting that
reduced activity in the PP2A-Rts1 subcomplex results in lst8Δ bypass. I then tested
whether rts1Δ and tpd3Δ mutations suppress tor2-21. Figure 5D shows that rts1Δ
suppresses a tor2-21 mutation by restoring cell growth at 37 °C. A tpd3Δ mutation led to
temperature-sensitive growth defects in the TOR2 wild-type strain used in my study;
therefore, I could not assay tor2-21 suppression by tpd3Δ. These findings indicate that
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mutations in genes encoding components of the PP2A-Rts1 subcomplex suppress
TORC2-deficiency.
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Figure 5. Mutations in TPD3, RTS1 and PPH21/22 suppress TORC2 deficiency.
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(A) Far11-HA interacts with Tpd3-myc and Pph21-myc. Cell lysates of far11Δ mutant
cells (BY4741 far11) expressing Far11-HA only (pZL2762), tpd3Δ far11Δ double mutant
cells (TPY633) coexpressing Far11-HA and Tpd3-myc (pTP242), and pph21/22Δ far11Δ
triple mutant cells coexpressing Far11-HA and Pph21-myc (pTP244) were subject to
immunoprecipitation with anti-myc antibody. IgG HC indicates the heavy chain of the
anti-myc antibody used for Co-IP. * denotes a likely truncation product of Far11.
(B) Mutations in TPD3 and RTS1 bypass lst8Δ. Serial dilutions of wild-type (WT,
RBY231), lst8Δ (RBY223), lst8Δ tpd3Δ (TPY625), lst8Δ rts1Δ (TPY648), and lst8Δ cdc55Δ
mutant (TPY732) cells carrying a centromeric plasmid encoding LST8 ([URA3 LST8],
pZL339) were grown on SD medium without or with 5-FOA.
(C) A pph21/22Δ double mutation bypasses lst8Δ. Serial dilutions of wild-type cells (WT,
BY4741) carrying an empty vector pRS416, lst8Δ single (BY4741 lst8), pph21/22Δ double
(BY4741 pph21/22) and lst8Δ pph21/22Δ triple (TPY622) mutant cells carrying a plasmid
encoding LST8 (pZL339) were tested for growth as described for panel B.
(D) An rts1Δ mutation suppresses tor2-21 at 37 °C. Serial dilutions of wild-type (SH100),
tor2-21 (SH121), rts1Δ (TPY665), and tor2-21 rts1Δ (TPY601) cells were grown on YPD
medium at 30 °C and 37 °C.
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2.4.8. far11Δ and rts1Δ restore phosphorylation of Slm1 in a tor2-21 mutant
One known function of TORC2 is its role in the organization of the actin
cytoskeleton possibly by phosphorylating Slm1, Slm2, and Ypk2. The data above show
that far11Δ, sac7Δ and rts1Δ mutations suppress a tor2-21 mutation and that Far11
interacts with PP2A. Therefore, I tested the possibility that Far11 may mediate
dephosphorylation of Slm1, Slm2, and/or Ypk2 via PP2A by evaluating the
phosphorylation states of Slm1, Slm2, and Ypk2 in wild-type, tor2-21, tor2-21 far11Δ,
tor2-21 sac7Δ, and tor2-21 rts1Δ mutant cells each expressing Slm1-HA, Slm2-HA, or
Ypk2-HA from their respective endogenous promoters. Ypk2 and Slm2’s
phosphorylation states did not differ between the wild-type and the tor2-21 mutant
grown at 37 °C (Appendix Fig. A8). Therefore, Ypk2 and Slm2 were not studied further.
Consistent with previous reports on the phosphorylation state of GFP-tagged Slm1 (5),
Figure 6A shows that Slm1-HA is phosphorylated: lambda protein phosphatase (λ
PPase) treatment resulted in increased levels of the faster mobility forms of Slm1-HA
with concomitant reduced levels of the slower mobility forms of Slm1-HA; phosphatase
inhibitors largely abolished the effect of λ PPase treatment. As reported previously,
Figure 6B shows that Slm1 is dephosphorylated in tor2-21 mutant cells grown at 37 °C
(5). Remarkably, far11Δ, but not sac7Δ, restored Slm1-HA phosphorylation to tor2-21
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mutant cells grown at 37 °C (Fig. 6B), implicating Far11 in Slm1 dephosphorylation and
suggesting that suppression of TORC2-deficiency by a sac7Δ mutation takes place
downstream of Slm1. Furthermore, Slm1-HA was phosphorylated in tor2-21 rts1Δ
mutant cells grown at 37 °C (Fig. 6C). These data suggest that Far11-PP2A-Rts1 may
antagonize TORC2 activity and decrease the levels of the phosphorylated form of the
TORC2 substrate Slm1.
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Figure 6. Mutations in RTS1 and FAR11, but not SAC7, restore SLM1 phosphorylation
in tor2-21 mutant cells.
(A) Slm1-HA is phosphorylated. Cell lysates from wild-type cells (SH100) expressing
Slm1-HA (pTP311) were prepared and treated with lambda protein phosphatase
(λPPase) with or without phosphatase inhibitors as described in Materials and
Methods. Slm1-HA was detected by Western blotting. * indicates phosphorylated Slm1.

(B) A mutation in FAR11, but not in SAC7, restores Slm1 phosphorylation in tor2-21
mutant cells grown at 37 °C. Indicated cells (WT, SH100; tor2-21, SH121; tor2-21 far11Δ,
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TPY116; tor2-21 sac7Δ, TPY110) expressing Slm1-HA were grown in YNBcasD medium
at 30 °C to mid-log phase and switched to 37 °C for 3h before cellular proteins were
processed for Western blotting.
(C) An rts1Δ mutation restores Slm1 phosphorylation in tor2-21 mutant cells grown at
37 °C. Indicated cells (WT, SH100; tor2-21, SH121; rts1Δ, TPY665; tor2-21 rts1Δ, TPY601)
expressing Slm1-HA were analyzed for Slm1-HA phosphorylation as described for
panel B.
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2.4.9. Effects of sac7Δ and far11Δ mutations on Tor2 kinase activity
Sac7 has been proposed to function downstream of TORC2. The genetic data
suggest that Far11-PP2A-Rts1 antagonizes TORC2 signaling. It is possible that Far11PP2A-Rts1 may function downstream of TORC2 and promote dephosphorylation of
TORC2 substrates. It is also likely that Far11-PP2A-Rts1 may function upstream of
TORC2 and negatively impact TORC2 activity. To differentiate between these two
possibilities, the activity of immunopurified Tor2 with a N-terminal 3xHA tag from
wild-type and isogenic far11Δ mutant cells was determined in an in vitro kinase assay
using Slm1 as a substrate. Slm1 has been reported to be a TORC2 substrate in in vitro
kinase assays (5, 37). For the assays, recombinant 6xHis-tagged Slm1was added to
kinase reactions with immunopurified HA-Tor2 and [γ-32P]-ATP. Figure 7 shows that
far11Δ has no significant effect on kinase activity of immunopurified HA-Tor2,
suggesting that Far11 functions at a site downstream of TORC2.
Similarly, I performed an in vitro kinase assay using HA-Tor2 from sac7Δ mutant
cells. Surprisingly, sac7Δ slightly increases kinase activity of immunopurified HA-Tor2
(Fig. 7). Mutations in SAC7 have been proposed to activate Rho1, which in turn
activates Pkc1 and the cell wall integrity MAP kinase cascade. Increased activity of Tor2
in sac7Δ mutant cells suggests positive feedback regulation in TORC2 signaling.
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Differential effects of sac7Δ and far11Δ mutations on Tor2 kinase activity further support
the notion that Sac7 and Far11 mediate TORC2 signaling through different mechanisms.
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Figure 7. In vitro phosphorylation of Slm1 by immunopurified HA-Tor2.
(A) Wild-type (SW70) and isogenic sac7Δ (TPY1246) and far11Δ (TPY1249) cells
expressing N-terminal 3xHA-tagged Tor2 from the TOR2 genomic locus were grow in
YPD medium. Slm1-His6 phosphorylation assays by HA-Tor2 were conducted as
described in Materials and Methods. Phospho-Slm1-His6 was detected by
autoradiography. Total Slm1-His6 and HA-Tor2 in the assays were detected by
Coomassie Blue staining and immunoblotting, respectively. The result of a mock kinase
assay using cell lysates from wild-type cells expressing native, nontagged Tor2 (TB50a)
was included in lane 1.
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(B) The amount of phospho-Slm1-His6 was normalized to that of HA-Tor2 and
graphed. Kinase assays were performed with HA-Tor2 from two independent cell
lysates and the error bar indicates the standard deviation.
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2. 5. Discussion
Lst8 is an essential protein that exists in both TOR kinase complexes. I found that
mutations in genes encoding the PP2A-Rts1 subcomplex and the Far3-7-8-9-10-11
complex bypass lst8Δ and TORC2-deficiency. Analysis of these mutants led me to
propose that the essential function of Lst8 is linked to TORC2. The Far3-7-8-9-10-11
complex components are partially conserved in Drosophila and mammals, and have
been reported to interact with PP2A phosphatase in the STRIPAK complex. I showed
that the Far3-7-8-9-10-11 complex and PP2A negatively regulate TORC2 signaling
possibly by mediating dephosphorylation of the TORC2 substrate Slm1, depicted by the
proposed model in Figure 8. My results not only demonstrate that the essential function
of Lst8 is only linked to TORC2, but more importantly, reveal a novel link between the
two major signaling protein complexes PP2A and TORC2.

2.5.1. The essential function of Lst8 is linked to TORC2, but not TORC1
Yeast Lst8 has been reported to be important for TORC2 complex integrity in vivo
and Tor2 kinase activity in vitro (126). Underlying its importance in TORC2 activity, the
presence of Lst8 in TORC2 has been reported in multiple organisms including yeast,
slime mold, worms, flies, and mammals (28). Consistently, my data demonstrate that
the essential function of Lst8 is linked to TORC2. Delocalization of Bit61 and Avo3 from
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punctate structures at the plasma membrane in lst8Δ mutant cells likely results from
compromised TORC2 integrity in the absence of Lst8, indicating that Lst8 is also
required for proper localization of the TORC2 complex.
Lst8 interacts with the kinase domain of Tor2 in yeast TORC2 (126). Since far11Δ
bypasses lst8Δ and tor2-21, but not tor2Δ, avo1Δ, and avo3Δ, my data suggest that neither
lst8Δ nor the temperature-sensitive tor2-21 mutation leads to total loss of TORC2
activity. This possibility helps explain my observation that far11Δ and rts1Δ can restore
Slm1 phosphorylation to tor2-21 mutant cells at the restrictive temperature: If tor2-21 led
to total loss of TORC2 activity and consequent loss of Slm1 phosphorylation, PP2A
inactivation could not restore Slm1 phosphorylation unless other protein kinases also
phosphorylate Slm1. In this scenario, TORC2 would share a redundant function with
the other putative kinase in phosphorylating Slm1 and may have another essential
function separate from its kinase activity, for example, by maintaining interactions with
other proteins to conduct downstream signaling.

Three TORC2 substrates in yeast are Slm1, Slm2, and Ypk2. A constitutively
active Ypk2 mutant can restore growth to tor2Δ mutant cells, leading to the proposal
that the essential function of TORC2 is mainly linked to Ypk2 phosphorylation (28, 66).
There is strong evidence that functionally redundant Slm1 and Slm2 are essential
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substrates of TORC2. Firstly, Slm1 has been reported to interact with TORC2 and to be
phosphorylated by TORC2 (5, 37). Secondly, TORC2-dependent phosphorylation of
Slm1 seems to correlate with its plasma membrane association (5). Slm1 contains a PH
domain that binds to multiply phosphorylated phosphoinositides and is required for
Slm1’s plasma membrane localization (37), and putative loss of plasma membrane
association of Slm1/2 leads to cell death. Thirdly, a sac7Δ mutation suppresses both a
tor2-21 mutation and a slm1Δ slm2Δ double mutation, and the actin cytoskeleton is
depolarized in both slm1/2 and tor2-21 mutant cells. Although I could not test whether
phosphorylation of Slm2 and Ypk2 in a tor2-21 mutant is restored by far11 and rts1
mutations, it is likely that due to mutations in Far11-PP2A, increased phosphorylation
of Slm1, Slm2, and/or Ypk2 leads to cell viability in TORC2-deficient cells.

The presence of Lst8 in TORC1 is conserved from yeast to mammals. In yeast,
Lst8 localizes not only to the TORC1 compartment at the vacuolar membrane, but also
to the TORC2 compartment as punctate structures at the plasma membrane (10). Similar
to its interaction with Tor2 in TORC2, in yeast and humans, Lst8 interacts with the Tor1
kinase domain in the TORC1 complex (1, 70). Therefore, the observation that Lst8 is not
required for TORC1-dependent expression of genes encoding ribosomal proteins and
Kog1 localization at the vacuolar membrane is surprising, raising the question: Is Lst8
required for TORC1 activity at all? Missense mutations in LST8 increase the expression
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of a subset of TORC1-target genes (25, 45). Therefore, Lst8 is likely to be required for
optimal TORC1 activity, but an lst8Δ mutation may not reduce TORC1 activity severely
enough to lead to cell death. In mammals, the role of Lst8 in mTORC1 is unclear. mLst8
knockdown in human immortalized cell lines suggested that mLst8 is important for
mTORC1 activity (70). Later in mice, mLst8 was found to be important for mTORC2,
but not mTORC1 function during mouse development (50). The discrepancy could be
attributed to the differences between a developing mouse embryo and an immortalized
human cell line. However, the conclusions concerning the role of Lst8 in both yeast and
mouse are similar: the essential function of Lst8 is linked to TORC2 but not TORC1.

2.5.2. Far3-7-8-9-10-11-PP2A as a negative regulator of TORC2 signaling
One of the important findings presented here is a negative regulatory role of the
Far3-7-8-9-10-11 complex and PP2A in TORC2 signaling. Considering the extensive
studies on PP2A and TORC2, it is surprising that, to my knowledge, this study may
represent the first to present a direct genetic interaction between TORC2 and PP2A.
More importantly, my data mirror a recent study in Drosophila demonstrating that the
Drosophila Far complex works in concert with PP2A in the regulation of a different
kinase pathway, the Hippo signaling pathway (96). Thus, PP2A regulation by the Far
protein complex appears to be evolutionarily conserved. In a proteomics study, the
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yeast Far11 orthologs, Fam40A and Fam40B (STRIP1/2) were isolated in the STRIPAK
complex, which also contains components of PP2A. Interestingly, far11Δ leads to the
strongest suppression of TORC2-deficiency, and among the six Far proteins, Far11 is the
most conserved. Far9 and Far10 are homologous proteins and their Drosophila and
mammalian orthologs show limited sequence homology, mostly in an FHA domain,
which is known to interact with phosphothreonine epitopes on target proteins (33). Far8
shows very limited sequence homology to striatin (48). The question remains: How
does the Far3-7-8-9-10-11 complex affect PP2A activity? Interaction between Far11 and
Tpd3, the scaffolding subunit of PP2A suggests that the Far complex may directly
regulate PP2A by either targeting the TORC2 substrate Slm1 and/or mediating PP2A
activity. Unlike slow cell growth phenotypes due to a tpd3Δ single or a pph21/22Δ
double mutation, mutations in FAR3, FAR7, FAR8, FAR9, FAR10,and FAR11 have little
or no growth defects, suggesting that the Far complex is not integral to PP2A activity. In
both the Drosophila study and this one, mutations in PP2A and/or Far components of the
STRIPAK complex lead to increased phosphorylation of target proteins. Thus, it is
possible that the Far complex might target certain substrates to PP2A.

This study demonstrates that Far11-PP2A-Rts1 modulates Slm1 phosphorylation
by counteracting the kinase activity of TORC2, providing a molecular mechanism to
explain how mutations in FAR11 and genes encoding PP2A-Rts1 components might
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suppress TORC2-deficiency. The calcineurin phosphatase also mediates Slm1
dephosphorylation and counteracts TORC2 signaling (19, 30, 87). It was further shown
that mutations in cnb1, encoding the regulatory subunit of calcineurin, suppress an avo3
temperature-sensitive mutation (4). It remains to be determined whether a cnb1
mutation restores phosphorylation of Slm1 to TORC2-deficient cells. Ypk2 is another
essential effector of TORC2. Mutations in calcineurin could potentially restore
phosphorylation of Ypk2 in avo3 mutant cells, thereby suppressing the avo3
temperature-sensitive growth phenotype. Furthermore, in a genome-wide study on
genetic interactions in yeast, mutations in PPG1, encoding a PP2A-like phosphatase,
also suppress TORC2-deficiency (7). Therefore, it is likely that these phosphatases may
work together to mediate TORC2 signaling.

Various genetic screens in fungi have isolated mutations in the Far complex. In
Neurospora crassa, a mutation in ham-2, the ortholog of yeast FAR11 leads to defects in
hyphal fusion (127). In Sordaria macrospora, mutations in PRO22, encoding the yeast
Far11 ortholog, generate a novel type of sterile mutant with a defect in ascogonial
septum formation (15). In yeast, mutations in FAR9/VPS64 and FAR11/YNL127w result
in vacuolar sorting defects (16), and mutations in FAR3, FAR7, FAR8, FAR10, and
FAR11 create long-lived mutants (36). In all of these studies, the underlying
mechanisms are unknown. In light of my findings, it is possible that these disparate
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phenotypes are due to the perturbation of PP2A activity and/or TORC2 signaling in
these mutants.
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Figure 8. A model for the regulation of TORC2 signaling by the Far3-7-8-9-10-11
complex and PP2A-Rts1.

TORC2 regulates the organization of the actin cytoskeleton via phosphorylation of Slm1
and Ypk1/2. Far3-7-8-9-10-11-PP2A-Rts1 antagonizes TORC2 signaling by promoting
Slm1 dephosphorylation. Proteins in bold were analyzed in this study.
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Table 2. S. cerevisiae strains used in Chapter 2.
Strain
ZLY2254

Genotype
MATa ura3Δ0 leu2Δ0 his3Δ1 met15Δ0
lst8::kanMX4 ade2Δ::HIS3 [pRS412LST8]
ZLY3081
MATα ura3Δ0 leu2Δ0 his3Δ1 met15Δ0
(WT)
lst8::kanMX4 ade2Δ::HIS3 [pRS412LST8]
TPY104
MATα ura3Δ0 leu2Δ0 his3Δ1 met15Δ0
(leb1)
lst8::kanMX4 ade2Δ::HIS3
leb1::Tn3::LEU2 [pRS412-LST8]
TPY103
MATα ura3Δ0 leu2Δ0 his3Δ1 met15Δ0
(leb2)
lst8::kanMX4 ade2Δ::HIS3
leb2::Tn3::LEU2 [pRS412-LST8]
ZLY423 (WT) MATa ade2-1 ura3 his3-11,15 leu2
lst8::LEU2 [pRS412-LST8]
TPY115
MATa ade2-1 ura3 his3-11,15 leu2
(far11 lst8)
lst8::LEU2 far11::kanMX4
TPY114
MATa ade2-1 ura3 his3-11,15 leu2
(far11)
lst8::LEU2 far11::kanMX4 [pRS412LST8]
TPY122
MATa ade2-1 ura3 his3-11,15 leu2
(fpr1)
lst8::LEU2 fpr1::kanMX4 [pRS412LST8]
ZLY2405
MATa ade2-1 ura3 his3-11,15 leu2
(sac7 lst8)
lst8::LEU2 sac7::kanMX4
ZLY2404
MATa ade2-1 ura3 his3-11,15 leu2
(sac7)
lst8::LEU2 sac7::kanMX4 [pRS412LST8]
ZLY2845
MATa ade2-1 ura3 his3-11,15 leu2
(sac7 lst8)
lst8::LEU2 sac7::kanMX4 [pRS412]
TWY680
MATa AVO3-GFP::kanR ura3 trp1
leu2 his3 ade2 can1-100
TWY696
MATa BIT61-GFP::HIS ura3 trp1 leu2
his3 ade2 can1-100
TWY748
MATa KOG1-GFP::HIS ura3 trp1 leu2
his3 ade2 can1-100
TPY1264
MATa sac7::kanMX4 far11::TRP1
(WT, no GFP) ura3 leu2 his3 ade2 trp1 can1-100
TPY1266
MATa sac7::HIS3 far11::TRP1
(lst8, no GFP) lst8::LEU2 ura3 leu2 his3 ade2 trp1
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Source
This study

Application

This study

Fig. 1

This study

Fig. 1

This study

Fig. 1

This study

Fig. 2A

This study

Fig. 2A

This study

Fig. 2A

This study

Fig. 2A

This study

Fig. 2A

This study

Fig. 2A-B

This study

Fig. 2B

(10)

This study

Fig. 2C

This study

Fig. 2C

can1-100
TPY369
MATa AVO3-GFP::kanR ura3 trp1
(AVO3-GFP) leu2 his3 ade2 can1-100 sac7::HIS3
far11::TRP1
TPY407 (lst8 MATa AVO3-GFP::kanR ura3 trp1
AVO3-GFP)
leu2 his3 ade2 can1-100 sac7::HIS3
far11::TRP1 lst8::LEU2
TPY358
MATa BIT61-GFP::HIS ura3 trp1 leu2
(BIT61-GFP) his3 ade2 can1-100 sac7::kanMX4
far11::TRP1
TPY366 (lst8 MATa BIT61-GFP::HIS ura3 trp1 leu2
BIT61-GFP)
his3 ade2 can1-100 sac7::kanMX4
far11::TRP1 lst8::LEU2
TPY371
MATa KOG1-GFP::HIS ura3 trp1 leu2
(KOG1-GFP) his3 ade2 can1-100 sac7::kanMX4
far11::TRP1
TPY413 (lst8 MATa KOG1-GFP::HIS ura3 trp1 leu2
KOG1-GFP)
his3 ade2 can1-100 sac7::kanMX4
far11::TRP1 lst8::LEU2
SY2227
MATa ade1-1 leu2-2,113 trp1 ura3-52
bar1 HIS3::pFUS1::HIS3 mfa2Δ1::FUS1-lacZ rad16::pGAL1::STE4
SY4078
SY2227 FAR7-myc13-KAN
<pSL2771>
SY4079
SY2227 FAR8-myc13-KAN
<pSL2771>
SY4080
SY2227 FAR9-myc13-KAN
<pSL2771>
SY4081
SY2227 FAR10-myc13-KAN
<pSL2771>
SY4082
SY2227 FAR11-myc13-KAN
<pSL2771>
TPY978
SY2227 FAR7-myc13-KAN [pRS416FAR11-HA]
TPY981
SY2227 FAR8-myc13-KAN [pRS416FAR11-HA]
TPY1001
SY2227 FAR9-myc13-KAN [pRS416FAR11-HA]
TPY1002
SY2227 FAR10-myc13-KAN
[pRS416-FAR11-HA]
TPY1003
SY2227 FAR11-myc13-KAN
[pRS416-FAR11-HA]
RBY231 (WT) MATα ura3 leu2 lys2 [pRS416-LST8]
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This study

Fig. 2

This study

Fig. 2

This study

Fig. 2C

This study

Fig. 2C

This study

Fig. 2C

This study

Fig. 2C

(68)

This study

Fig. 3A

This study

Fig. 3A

This study

Fig. 3A

This study

Fig. 3A

This study

Fig. 3A

This study

Fig. 3B,

RBY223 (lst8) MATα ura3 leu2 lys2 lst8::LEU2
[pRS416-LST8]
MOY142 (lst8 MATα ura3 leu2 lys2 lst8::LEU2
far3)
far3::kanMX4 [pRS416-LST8]
MOY145 (lst8 MATα ura3 leu2 lys2 lst8::LEU2
far7)
far7::kanMX4 [pRS416-LST8]
MOY146 (lst8 MATα ura3 leu2 lys2 lst8::LEU2
far8)
far8::kanMX4 [pRS416-LST8]
MOY169 (lst8 MATα ura3 leu2 lys2 lst8::LEU2
far9)
far9::kanMX4 [pRS416-LST8]
MOY149 (lst8 MATα ura3 leu2 lys2 lst8::LEU2
far10)
far10::kanMX4 [pRS416-LST8]
MOY150 (lst8 MATα ura3 leu2 lys2 lst8::LEU2
far11)
far11::kanMX4 [pRS416-LST8]
SH100 (WT)
MATa leu2-3,112 ura3-52 rme1 trp1
his4 HMLa ade2 tor2::ADE2
[YCplac111::TOR2]

This study

5B
Fig. 3B,
5B
Fig. 3B

This study

Fig. 3B

This study

Fig. 3B

This study

Fig. 3B

This study

Fig. 3B

This study

Fig. 3B

(57)

Fig. 3C, 4,
5D, 6A,
6B, 6C,
Table 1
Fig. 3C, 4,
5D, 6B,
6C, Table
1

This study

SH121 (tor221)

MATa leu2-3,112 ura3-52 rme1 trp1
his4 HMLa ade2 tor2::ADE2
[YCplac111::tor2-21]

SH221 (tor1
tor2-21)

MATa leu2-3,112 ura3-52 rme1 trp1
his3 HMLa ade2 tor1::HIS3
tor2::ADE2 [YCplac111::tor2-21]
SH121 far3::kanMX4

This study

Fig. 3C

SH121 far7::kanMX4

This study

Fig. 3C

SH121 far8::kanMX4

This study

Fig. 3C

SH121 far9::kanMX4

This study

Fig. 3C

SH121 far10::kanMX4

This study

Fig. 3C

SH121 far11::kanMX4

This study

Fig. 3C,
4C, 6B

SH121 sac7::kanMX4

This study

Fig. 4A,
4C, 6B.

TPY157
(tor2-21 far3)
TPY147
(tor2-21 far7)
TPY213
(tor2-21 far8)
TPY207
(tor2-21 far9)
TPY151
(tor2-21
far10)
TPY116
(tor2-21
far11)
TPY110
(tor2-21 sac7)
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TPY311
(tor2-21
far11)
TPY301
(tor2-21 sac7
far11)
TPY680
(tor2-21 far11
rom2)
BY4741
BY4741 far11
TPY633
TPY632

SH121 far11::TRP1

This study

SH121 sac7::kanMX4 far11::TRP1

This study

SH121 rom2::kanMX4 far11::TRP1

This study

MATa ura3 leu2 his3 met15
BY4741 far11::kanMX4
BY4741 tpd3::kanMX4 far11::HIS3
BY4741 pph21::kanMX4
pph22::kanMX4 far11::HIS3
TPY625 (lst8 MATα ura3 leu2 lys2 lst8::LEU2
tpd3)
tpd3::kanMX4 [pRS416-LST8]
TPY648 (lst8 MATα ura3 leu2 lys2 lst8::LEU2
rts1)
rts1::kanMX4 [pRS416-LST8]
TPY732 (lst8 MATα ura3 leu2 lys2 lst8::LEU2
cdc55)
cdc55::kanMX4 [pRS416-LST8]
BY4741 (WT) MATa ura3 leu2 his3 met15 [pRS416]
BY4741 (lst8) MATa ura3 leu2 his3 met15
lst8::LEU2 [pRS416-LST8]
BY4741
MATa ura3 leu2 his3 met15
(pph21/22)
pph21::kanMX4
pph22::kanMX4[pRS416-LST8]
TPY622 (lst8 MATa ura3 leu2 his3 met15
pph21/22)
lst8::LEU2 pph21::kanMX4
pph22::kanMX4[pRS416-LST8]
TPY665 (rts1) MATa leu2-3,112 ura3-52 rme1 trp1
his4 HMLa ade2 tor2::ADE2
rts1::kanMX4 [YCplac111::TOR2]
TPY601
MATa leu2-3,112 ura3-52 rme1 trp1
(tor2-21 rts1) his4 HMLa ade2 tor2::ADE2
rts1::kanMX4 [YCplac111::tor2-21]
TB50a
MATa leu2–3,112 ura3–52 trp1 his3
rme1 HMLa
SW70
TB50a 3HA-TOR2
TPY1246
TB50a 3HA-TOR2 sac7::HIS3
TPY1249
TB50a 3HA-TOR2 far11::TRP1
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Table 1
Fig. 4C,
4D, Table
1
Fig. 4C,
Table 1
Fig. 4D

Yeast Genome
Deletion Project Fig. 5A
This study
Fig. 5A
This study
Fig. 5A
This study

Fig. 5B

This study

Fig. 5B

This study

Fig. 5B

This study
This study

Fig. 5C
Fig. 5C

This study

Fig. 5C

This study

Fig. 5C

This study

Fig. 5D,
6C

This study

Fig. 5D,
6C

(126)

Fig. 7

This study
This study

Fig. 7
Fig. 7
Fig. 7

Table 3. Plasmids used in Chapter 2
Plasmid
pZL2422
pZL2550
pZL1255
pZL2762

pTP242

pTP244

pZL339
pTP311

pTP377

pTP271

pZL3031

Description
pRS416-SAC7
pRS416-FAR11
pRS412-LST8
pRS416-FAR11-HA, expressing Far11
from its own promoter with a 3xHA tag
at the C-terminus.
pRS415-ADH1-TPD3-myc, expressing
Tpd3 from the ADH1 promoter with a
3xmyc tag at the C-terminus.
pRS415-PPH21-myc, expressing
Pph21 from its own promoter with a
3xmyc tag at the C-terminus.
pRS416-LST8
pRS416-SLM1-HA, expressing Slm1
from its own promoter with a 3xHA tag
at the C-terminus.
pRS416-SLM2-HA, expressing Slm2
from its own promoter with a 3xHA tag
at the C-terminus.
pRS416-YPK2-HA, expressing Ypk2
from its own promoter with a 3xHA tag
at the C-terminus.
pET24a-SLM1, expressing Slm1 with
a C-terminal 6xHis tag under the
control of an IPTG-inducible promoter.
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Reference
This study
This study
This study
This study

Application
Fig. 1
Fig. 1
Fig. 2A-B
Fig. 3A, 5A

This study

Fig. 5A

This study

Fig. 5A

(77)
This study

Fig. 3B, 5B
Fig. 6A

This study

Fig. 6

This study

Fig. 6

This study

Fig. 7

CHAPTER 3. TIERED ASSEMBLY OF THE
YEAST FAR3-7-8-9-10-11 COMPLEX AT THE
ENDOPLASMIC RETICULUM
3.1. Summary
TOR (target of rapamycin) signaling is a conserved, essential pathway
integrating nutritional cues with cell growth and proliferation. The TOR kinase exists in
two distinct complexes, TORC1 and TORC2. It has been reported that protein
phosphatase 2A (PP2A) and the Far3-7-8-9-10-11 complex (Far complex) negatively
regulate TORC2 signaling in yeast. The Far complex, originally identified as factors
required for pheromone-induced cell cycle arrest, and PP2A form the yeast counterpart
of the STRIPAK complex, which was first isolated in mammals. The cellular localization
of the Far complex has yet to be fully characterized. Here I show that the Far complex
localizes to the endoplasmic reticulum (ER) by analyzing functional, GFP-tagged Far
proteins in vivo. I found that Far9 and Far10, two homologous proteins each with a tailanchor domain, localize to the ER in mutant cells lacking the other Far complex
components. Far3, Far7, and Far8 form a subcomplex, which is recruited to the ER by
Far9/10. The Far3-7-8 complex in turn recruits Far11 to the ER. Finally, I show that the
tail-anchor domain of Far9 is required for its optimal function in TORC2 signaling. My
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study reveals tiered assembly of the yeast Far complex at the ER and a function for Far
complex’s ER localization in TORC2 signaling.

3.2. Introduction
Protein phosphorylation plays important roles in many cellular processes.
Protein phosphorylation is catalyzed by specific protein kinases and protein
dephosphorylation is carried out by protein phosphatases. Thus, the phosphorylation
state of proteins is finely controlled by the opposing activities of protein kinases and
phosphatases. Multiple mechanisms exist to fine-tune the activity of these protein
kinases and phosphatases through the regulation of their expression levels, their
activity, cellular localization, and availability to substrates, among others. Recently, a
large multi-protein complex known as the striatin-interacting phosphatase and kinase
(STRIPAK) complex was found in mammals. STRIPAK contains PP2A catalytic and
scaffolding subunits, striatins, the striatin-associated protein Mob3, two homologous
novel proteins STRIP1 and STRIP2, members of the germinal center kinase III family of
Ste20 kinases, and the Cerebral Cavernous Malformation 3 (CCM3) protein (48, 96). The
STRIPAK assembly maintains mutually exclusive interactions with either the CTTNBP2
(cortactin-binding protein 2) proteins or a second subcomplex consisting of
sarcolemmal membrane-associated protein (SLMAP) and two related coiled-coil
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proteins

SIKE

and

FGFR1OP2.

The

N-terminal

region

of

CCM3

mediates

heterodimerization with Ste20 kinases, and its C-terminal domain interacts with striatin
(24, 39, 67, 75, 131), which also interacts with the regulatory and catalytic subunits of
PP2A, thus bridging a kinase to a phosphatase. This arrangement likely facilitates the
regulation of the activity of protein kinases by PP2A (47, 67). Both Striatin 3 and STRIP1
localize to the Golgi and depletion of either results in similar defects suggesting they
perform similar functions in regulation of Golgi morphology and mitosis (42, 67). The
SLMAP gene has several splice variants, encoding tail-anchored membrane proteins
that associate with the sarcolemmal membrane in muscle cells, the endoplasmic
reticulum and the mitochondrial membrane in non-muscle cells, and the centrosome
and the outer nuclear envelope (21, 42, 52, 89, 124). SLMAP is required for myoblast
fusion, centrosome function, and structural arrangement of the excitation-contraction
coupling apparatus in cardiomyocytes (42, 51-53). Much remains to be determined
about the role of STRIPAK components and the regulation and substrates of STRIPAK.

Orthologs of mammalian STRIPAK components have been reported to exist in
many eukaryotes. The Drosophila STRIPAK complex has been reported to be involved in
Hippo signaling by mediating phosphorylation of the Hippo kinase and the
transcriptional activator Yorkie (96).

In Neurospora crassa, orthologs of STRIPAK

complex components are required for hyphal fusion (108, 127). In the ascomycete
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Sordaria macrospora, the STRIPAK complex is required for sexual development and
vegetative hyphal fusion (14, 15). In the fission yeast Schizosaccharomyces pombe,
components of the STRIPAK complex localize to the mitotic spindle pole body in early
mitosis and are required for the establishment of asymmetry of the septation initiation
network, a conserved signaling pathway that is required for cytokinesis and mitotic
transitions (42, 109).

In the budding yeast Saccharomyces cerevisiae, the STRIPAK complex has been
reported to mediate pheromone signaling, the TORC2 signaling pathway, and the
toxicity due to expression of human Caspase-10 in yeast (7, 68, 76, 93). The yeast
STRIPAK complex contains Far3, Far7, Far8, Far9, Far10, Far11, Tpd3 (the A scaffolding
subunit of PP2A), and Pph21/22 (the two redundant catalytic subunits of PP2A) (68, 73,
76, 93, 119). Far11 is an ortholog of human STRIP1/2; Far8 shares limited sequence
similarity to human striatins; Far9 and Far10 are homologous tail-anchored proteins
similar to human SLMAP (Table 1) (9, 48). Yeast cells secrete pheromones to induce cell
cycle arrest to prepare for mating as part of the fungal life cycle (38). Mutations in FAR
genes lead to increased resistance to pheromone-induced cell cycle arrest (59, 68), but
the underlying mechanism is still unclear. TOR (target of rapamycin) kinases are
conserved in eukaryotes and exist in two distinct multi-protein complexes, TORC1 and
TORC2 (74, 80), and mutations in the yeast STRIPAK complex components lead to
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suppression of cell lethality specifically due to TORC2-deficiency possibly by restoring
phosphorylation of TORC2 substrates Slm1, Slm2, Ypk1 and Ypk2 (7, 37, 90, 93). The
role of STRIPAK in human Caspase-10 induced toxicity in yeast likely results from
promoting Atg13 dephosphorylation and subsequent activation of autophagy (65, 76).

In yeast, Far3, Far7, Far8, Far9, Far10 and Far11 have been reported to form a
complex (68, 73, 93). However, it is unclear how these proteins assemble together to
form the final complex, and identification of the cellular component of this complex
could potentially provide insights into the mechanism of its function. Cellular
localization of subsets of the Far complex components has been reported in three
different studies, however the results were not consistent (9, 61, 76). A genome-wide
study on the localization of yeast proteins found that Far3, Far7, and Far8 localize to the
ER (61). In that study, Far9 was shown to be localized in the cytoplasm, Far10
localization was ambiguous, and there was no data on Far11. In another study, Beilharz
et al. showed that Far9 localizes to the ER and that Far10 is found in clusters within the
bounds of the ER (9). In the third reported study on the localization of Far proteins,
Far11 was reported to co-localize with Chc1, a late-Golgi protein, Far3 with Cop1, an
early Golgi protein, and Far9 with Sec13, an ER-to-Golgi protein that is located on ERderived transport vesicles (76). To gain insights into how the Far proteins assemble into
a complex and address the inconsistency in their cellular localization, I constructed
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functional GFP-tagged Far proteins and analyzed their localization in various far
mutants. My data show that all of the Far proteins localize in a tiered fashion at the
endoplasmic reticulum and ER localization of Far9 is required for its optimal function in
TORC2 signaling.
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Table 1. Components of the STRIPAK complex in mammals and yeast
Description

Mammals

Yeast

PP2A A subunit

PR65A/PR65B

Tpd3

PP2A B”’ subunit

Striatin/ Striatin-3/

Far8

Striatin-4
PP2A C subunit

PP2A Cα and Cβ

Pph21, Pph22

Novel protein

STRIP1/STRIP2

Far11

Tail-anchored protein

SLMAP

Far9/Far10

Coiled-coil domain protein

SIKE, FGFR1OP2

Far3, Far7

Striatin-associated protein

Mob3

Mob1

Ste20 family kinase

STK24/STK25/Mst4

Kic1

Cavernous cerebral

CCM3

?

CTTNBP2

?

malformation protein 3
Cortactin-binding protein 2

(Proteins in italics are orthologs of the respective mammalian proteins but
have not yet been confirmed to be part of the yeast STRIPAK complex)
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3.3. Materials and methods
3.3.1. Strains, plasmids, and growth media and growth conditions
Yeast strains and plasmids used in this study are listed in Table 2 and 3,
respectively. Yeast cells were grown in SD (0.67% yeast nitrogen base plus 2% dextrose),
YNBcasD (SD medium plus 1% casamino acids), or YPD (1% yeast extract, 2% peptone,
2% dextrose) medium at temperatures as indicated in the text and in the figure legends.
When necessary, amino acids, adenine, and/or uracil were added to the growth medium
at standard concentrations to cover auxotrophic requirements (2).

3.3.2. Cellular extract preparation and co-immunoprecipitation
Total cellular protein extracts were prepared by disrupting yeast cells in
extraction buffer (1.85 N NaOH–7.5% β-mercaptoethanol) followed by precipitation
with trichloroacetic acid as described (129). For co-immunoprecipitation experiments,
cellular lysates were prepared in IP buffer (50 mM Tris-HCl pH 7.6, 150 mM NaCl, 0.5%
Triton X-100, and protease inhibitors). Cell extracts (~3 mg proteins) were incubated at 4
°C for 1 h with anti-myc antibody (9E10, Roche) or anti-HA antibody (12CA5, Roche) as
indicated, after which 30 µl of a 50% slurry of protein G-Sepharose (Roche) was added
to each sample and the samples were further incubated at 4 °C for 2 h. Washed
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immunoprecipitates bound to the Sepharose beads were released by boiling in 1X SDSPAGE loading buffer. The released immune complexes were analyzed by SDS-PAGE
and immunoblotting. myc, HA, and GFP-tagged proteins were probed with anti-myc
antibody 9E10, high affinity anti-HA antibody 3F10 (Roche), and anti-GFP antibody B-2
(Santa Cruz Biotechnology, Inc), respectively. Chemiluminescence images of Western
blots were captured using the Bio-Rad Chemi-Doc photo documentation system (BioRad) and processed using Bio-Rad Quantity One software. Experiments were repeated
at least twice.

3.3.3. Fluorescence microscopy
Fluorescence of GFP and RFP-tagged proteins was analyzed in live cells grown
in SD medium to the mid-logarithmic growth phase by fluorescence microscopy. Cells
were concentrated by centrifugation at 5000g for 2 minutes and fluorescence images
were immediately captured using a Nikon Eclipse E800 microscope equipped with an
HBO 100 W/2 mercury arc lamp, a Nikon Plan Fluor 100x objective lens, a Photometrics
Coolsnap fx CCD camera, and a Nikon B-2E/C filter set (excitation light wavelengths
465-495 nm, emission light wavelengths 515-555 nm, dichromatic mirror cut-on
wavelength 505 nm) for GFP images and a Y-2E/C filter set (excitation light
wavelengths 540-580 nm, emission light wavelengths 600-660 nm, dichromatic mirror
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cut-on wavelength 595 nm) for RFP images. Digital images were acquired using the
Metamorph Imaging Software and processed using ImageJ (NIH) and Adobe
Photoshop software. Experiments were repeated at least twice.

3.3.4. Pheromone response halo assay
Sensitivity to the mating pheromone α-factor was assayed by standard plate halo
assays as previously described (59, 111). Briefly, 2 µg of α-factor was applied to a sterile
filter paper disc placed onto a lawn of 1x106 cells spread on a YNBcasD plate. Halo
formation was documented after 3 days of cell growth. Experiments were repeated at
least twice.

3.4. Results
3.4.1. GFP-tagged Far3, Far7, Far8, Far9, Far10, and Far11 localize to the
Endoplasmic Reticulum
Elucidating the cellular localization of the Far Complex thus far has not been
straight forward. Several studies report inconsistent data with the components of the
Far complex localizing to different cellular compartments from one study to the next (9,
61, 76). Furthermore, none of the studies comprehensively analyzed the intracellular
localization of all components of the complex. In all cases, fluorescent tags were fused to
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each Far protein to localize each component. I considered two possibilities that could
result in disparity of the cellular localization patterns of the Far proteins and designed
the experiment to minimize these complications. First, the functionality of a protein can
be inhibited by the addition of a tag. Therefore functionality of the fusion proteins
should be determined. The functionality of the fusions of the previous studies was not
indicated therefore, it is possible that if their functionalities were not tested and the
fusions were not functional the proteins could show inconsistent cellular localizations.
Another factor that could affect the localization of a fusion protein is the placement of
the fluorescent tag. For instance, Far9 and Far10 contain a hydrophobic tail-anchor
domain, and the addition of a fluorescent protein at the C-terminal end of Far9 and
Far10 would affect their cellular localization. Therefore, differential cellular localization
of Far9 and Far10 could be attributed to the position of the fluorescent protein tag such
as in Lisa-Sanatmaria et al.’s study where the authors added a C-terminal CFP tag to
Far9 and found Far9 to localize on transport vesicles between ER and the Golgi
inconsistent with previous studies (9, 61). Accordingly, I generated N-terminal GFPtagged Far9 and Far10 fusion constructs and C-terminal GFP-tagged Far3, Far7, Far8
and Far11 constructs on centromeric plasmids and determined their functionality and
cellular localization. Expression of GFP-tagged Far3, Far7, Far8 and Far11 fusion
proteins was under the control of their respective endogenous promoters. Expression of
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GFP-tagged Far9 and Far10 was under the control of a stronger but still relatively weak
promoter of MKS1 (105) due to my initial observations that N-terminal GFP-tagged Far9
and Far10 under the control of their endogenous promoters did not yield enough signal
to determine their cellular localization. To minimize potential interference of GFP with
the functionality and thus localization of Far proteins, I also introduced a 10-alanine
linker between the Far proteins and the GFP tag.

I first determined the functionality of GFP-tagged Far fusion proteins by a plate
halo assay (Fig. 1A). Wild-type mating type a cells normally arrest cell growth around a
paper disc infused with α-factor and create a cell-free zone in the shape of a halo. I
generated far3, far7, far8, far9, far10, and far11 single deletion mutants and found that
they became resistant to α-factor-induced cell cycle arrest, which was manifested by
increased cell growth around the disc containing α-factor, consistent with previous
results (68). After these farΔ mutants were transformed with centromeric plasmids
encoding respective wild-type FAR genes tagged with GFP, the resultant transformants
now became as sensitive to α-factor as wild-type cells, indicating that GFP-tagged Far3,
Far7, Far8, Far9, Far10, and Far11 proteins were all functional.

I next examined the cellular localization of the GFP-tagged Far proteins in their
respective far deletion mutant strains. The right column of Figure 1B shows that all
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exhibited localizations suggestive of perinuclear and periplasmic endoplasmic
reticulum (ER) localization. To support this assumption, in cells expressing GFP-tagged
Far proteins, I coexpressed C-terminal red fluorescent protein (RFP)-tagged Shr3, an
ER-localized chaperone for packaging amino acid permeases into COPII-coated
transport vesicles (71). Figure 1B shows that Shr3-RFP and each of the six Far-GFP
fusion proteins colocalize, indicating that the Far complex localizes to the ER. I
expressed GFP-tagged Far proteins in respective far deletion mutant strains of two other
strain backgrounds, BY4741, which is derived from S288c, and SY2227 (68), and I found
that in these strains, GFP-tagged Far proteins also localized to the ER (data not shown),
indicating that ER localization of the Far complex is not strain dependent.
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GFP-FAR10

far10Δ
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FAR11-GFP

far11Δ

Vector

Far11

Figure 1. The Far3,7,8,9,10,11 complex localizes to the ER.
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Shr3-RFP

Merge

(A) GFP-tagged FAR constructs complement respective far deletion mutations by halo
assay. Wild-type (WT, SY2227) and isogenic farΔ mutant cells (far3Δ, TPY1010; far7Δ,
TPY1013; far8Δ, TPY1015; far9Δ, TPY1048; far10Δ, TPY1072; far11Δ, SY4064) carrying the
empty vector pRS416 (Vector) or plasmids encoding respective FAR-GFP fusions (FAR3GFP, pTP143; FAR7-GFP, pTP164; FAR8-GFP, pTP131; GFP-FAR9, pTP179; GFP-FAR10,
pTP203; FAR11-GFP, pZL2564) were grown on YNBcasD medium in the presence of a
paper filter disc containing α-factor as described in experimental procedures.
(B) Colocalization of GFP-tagged Far proteins with ER-localized Shr3-RFP. farΔ mutant
cells (far3Δ, TPY157; far7Δ, TPY147; far8Δ, TPY213; far9Δ, TPY357; far10Δ, TPY151;
far11Δ, TPY116) coexpressing respective GFP-tagged Far proteins as described for panel
(A) and RFP-tagged Shr3 (pTP201) were grown in SD medium and observed by
fluorescence microscopy. GFP and RFP fluorescence images were captured and
processed using the same parameters for each channel. Vacuolar autofluorescence in the
RFP channel was sometimes observed.
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3.4.2. Far9 and Far10 localize to the ER independently of the other Far proteins
To better understand how the Far complex is organized on the ER, I sought to
determine which Far protein(s) establishes a foothold on the ER. To this end, I analyzed
the cellular localization of individual GFP-tagged Far proteins in a far3/7/8/9/10/11Δ
sextuple mutant strain. Figure 2 shows that Far3-GFP, Far7-GFP, Far8-GFP, and Far11GFP, when expressed individually in the sextuple mutant strain, did not exhibit ER
localization, indicating that they were unable to localize to the ER in the absence of
other Far complex components. In contrast, GFP-Far9 and GFP-Far10 fusion proteins
could still localize to the ER in the sextuple mutant, indicating that Far9 and Far10
establish ER localization for the complex. Far9 and Far10 contain a tail-anchor domain
at their C-termini. Therefore, it is not surprising that they may function as the ER
anchor for the Far complex. Furthermore, the localization of Far9 and Far10 on the ER
when expressed individually in the sextuple mutant suggests that these two
homologous proteins do not require hetero-oligomerization for ER recruitment.
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Far3-GFP

Far7-GFP

Far8-GFP

GFP-Far9

GFP-Far10

Far11-GFP

far3Δ
far7Δ
far8Δ
far9Δ
far10Δ
far11Δ

Figure 2. Far9 and Far10, but not Far3, Far7, Far8 or Far11, are able to localize to the ER
in the absence of the other Far complex components.

Sextuple farΔ mutant cells (TPY845) expressing GFP-tagged Far proteins as indicated
were grown in SD medium and observed by fluorescence microscopy.
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3.4.3. Tiered assembly of the components of the Far complex at the ER
To further characterize the organization of the Far complex on the ER, I sought to
determine the order in which the rest of the complex localizes to the ER. To achieve this,
I determined whether ER localization of GFP-tagged Far3, Far7, Far8, or Far11 could be
altered by the absence of just one of the other five Far complex components.
Accordingly, I characterized the cellular localization of Far3-GFP in far3Δ far7Δ, far3Δ
far8Δ, far3Δ far9Δ, far3Δ far10Δ, and far3Δ far11Δ double deletion mutant cells. Far3-GFP
localization at the ER was abolished by far7Δ, far8Δ, far9Δ, and far10Δ mutations but still
showed normal ER localization in a far11Δ mutant, indicating that ER localization of
Far3-GFP requires Far7, Far8, Far9 and Far10, but not Far11 (Fig. 3A). Using the same
strategy, I determined the cellular localization of Far7-GFP, Far8-GFP, and Far11-GFP in
respective double deletion mutant cells. Likewise, ER localization of Far7-GFP and Far8GFP was abolished by all respective farΔ mutations except a far11Δ mutation (Fig. 3B-C).
Interestingly, ER localization of Far11-GFP was disrupted by the deletion of any of the
other five Far complex components (Fig. 3D), suggesting that Far11 is the most
peripheral component of this complex at the ER. These data also suggest that Far3, Far7,
Far8, and Far11 are peripheral membrane proteins since their ER localization requires
the tail-anchored proteins Far9 and Far10. This possibility was supported by my initial
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observation early in my studies that the localization of GFP-tagged Far3, Far7, Far8, and
Far11 became more cytoplasmic when they were expressed in wild-type cells in
comparison to respective deletion mutant cells, suggesting that these four GFP-tagged
Far proteins compete with their non-tagged counterparts for Far9/10-dependent ER
localization (data not shown). The interdependence of Far3, Far7, and Far8 for ER
localization also suggests that they might form a subcomplex before their ER
recruitment. Together, these data suggest that the Far complex assembles at the ER in
the spatial order of Far9/10, Far3/7/8, and then Far11.
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C

Far8-GFP
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Figure 3. Cellular localization of GFP-tagged Far3, Far7, Far8 or Far11 in the absence of
individual components of the Far complex.
(A) Localization of Far3-GFP in the mutant strains as indicated (far3Δ, TPY1010; far3Δ
far7Δ, TPY1358; far3Δ far8Δ, TPY1361; far3Δ far9Δ, TPY1348; far3Δ far10Δ, TPY1363; far3Δ
far11Δ TPY1402). (B) Localization of Far7-GFP in the mutant strains as indicated (far7Δ,
TPY1013; far7Δ far3Δ, TPY1408; far7Δ far8Δ, TPY1366; far7Δ far9Δ, TPY1350; far7Δ far10Δ,
TPY1368; far7Δ far11Δ TPY1352). (C) Localization of Far8-GFP in the mutant strains as
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indicated (far8Δ, TPY1015; far8Δ far3Δ, TPY1369; far8Δ far7Δ, TPY1370; far8Δ far9Δ,
TPY1351; far8Δ far10Δ, TPY1373; far8Δ far11Δ TPY1405). (D) Localization of Far11-GFP in
the mutant strains as indicated (far11Δ, SY4064; far11Δ far3Δ, TPY1374; far11Δ far7Δ,
TPY1377; far11Δ far8Δ, TPY1406; far11Δ far9Δ, TPY1410; far11Δ far10Δ, TPY1379). All cells
were grown in SD medium and observed by fluorescence microscopy.
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3.4.4. Far3, Far7, and Far8 form a subcomplex
To test whether Far3, Far7, and Far8 are able to form a subcomplex independent
of Far9, Far10 and Far11, I determined whether Far3, Far7 and Far8 could form pairwise interactions in far3/7/8/9/10/11Δ sextuple mutant cells by co-immunoprecipitation.
Accordingly, Far3-GFP was coexpressed with either 3xHA epitope-tagged Far7 or Far8
and Far7-GFP was coexpressed with either 3xHA epitope-tagged Far3 or Far8 in
far3/7/8/9/10/11Δ sextuple mutant cells. HA-tagged proteins from cell lysates were
immunoprecipitated with anti-HA antibody and immunoprecipitates were probed with
anti-GFP antibody to detect GFP-tagged proteins via Western blotting. I found that
Far7-HA, but not Far8-HA, was able to pull down Far3-GFP (Fig. 4A, lane 1-3).
Similarly, Far3-HA, but not Far8-HA, was able to pull down Far7-GFP (Fig. 4A, lane 46). Together, these data indicate that Far3 and Far7 are able to interact with each other
in the absence of the other Far complex components.

Far8 has been reported to interact with Far3 and Far7 by yeast two-hybrid and
co-immunoprecipitation analyses in wild-type strains (68, 73). Although I carried out
the interaction analysis between Far8 and Far3 or Far7 in sextuple mutant cells, which
were not used in previous studies, the failure to detect their interactions in such cells
was still surprising because these three proteins appear to require each other to for ER
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localization as shown in Figure 3. One possibility is that Far8 may only bind to the Far37 complex. To test this hypothesis, I first confirmed whether Far8 interacts with Far3 or
Far7 in respective double deletion mutant cells. I generated a far3Δ far8Δ double mutant
carrying plasmids encoding FAR3-HA and FAR8-GFP. Figure 4B shows that Far8-GFP
was co-immunoprecipitated specifically with Far3-HA (compare lane 1 and 2).
Similarly, I found that Far8-GFP specifically interacts with Far7-HA in a far7Δ far8Δ
double mutant (Fig. 4B, lane 3-4). I next examined whether Far8 interacts with the Far3Far7 complex in the sextuple mutant. I coexpressed Far3-HA, Far8-GFP and non-tagged
Far7 in far3/7/8/9/10/11Δ sextuple mutant cells and found that expression of Far7 in the
sextuple mutant was sufficient for Far3-HA to interact with Far8-GFP (Fig. 4C, compare
lane 1-2). Similarly, reintroduction of Far3 into sextuple mutant cells coexpressing Far7HA and Far8-GFP also enabled an interaction between Far7 and Far8 (Fig. 4C, compare
lane 3-4). These data together indicate that Far3, Far7, and Far8 form a subcomplex in
the absence of the other components of the Far complex.
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Figure 4. Far3, Far7, and Far8 form a subcomplex.
(A) Far3 and Far7 are able to interact in the absence of Far8, Far9, Far10, and Far11. Cell
lysates of sextuple farΔ mutant cells (TPY845) coexpressing Far3-GFP (pTP143) and
Far7-HA (pTP646) or Far8-HA (pTP658), Far7-GFP (pTP164) and Far3-HA (pTP655) or
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Far8-HA (pTP658) as indicated were subjected to immunoprecipitation with anti-HA
antibody and epitope-tagged proteins were detected by immunoblotting. * and **
indicate the heavy chain of the anti-HA antibody used for immunoprecipitation that
was detected by goat anti-mouse IgG light chain specific and standard secondary
antibody, respectively.

(B) Far8 interacts with Far3 or Far7 in the presence of the other Far complex
components. far3/8Δ mutant cells expressing Far8-GFP (TPY1369) without or with Far3HA and far7/8Δ mutant cells expressing Far8-GFP (TPY1370) without or with Far7-HA
were analyzed for interactions between Far8-GFP and Far3-HA or Far7-HA by
immunoprecipitation and immunoblotting.
(C) Far8 interacts with the Far3-7 complex. Cell lysates of sextuple farΔ mutant cells
expressing epitope-tagged and non-tagged proteins as indicated were subjected to
immunoprecipitation with anti-HA antibody. GFP- and HA- tagged proteins were
detected by immunoblotting.

(D) Model of assembly of the Far3-7-8 subcomplex.
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3.4.5. Interaction between Far9 and Far11 requires the Far3-7-8 subcomplex
ER localization of Far11-GFP was disrupted by deletion of any of the other Far
complex components as shown in Figure 3D. These findings along with the findings
that Far3, Far7, and Far8 form a subcomplex suggest that the Far3-7-8 subcomplex may
bridge the interaction of Far11 and Far9/10 at the ER. To test this possibility, interaction
between myc-tagged Far9 and HA-tagged Far11 was analyzed in far9Δ far11Δ double
mutant cells without (WT) or with an additional mutation of far3Δ, far7Δ, or far8Δ. Far9myc was immunoprecipitated from cell lysates and immunoprecipitates were probed
with anti-HA antibody to detect Far11-HA via Western blotting. Figure 5 shows that
Far11-HA was co-immunoprecipitated with Far9-myc and deletion of FAR3, FAR7, or
FAR8 greatly reduced their interaction. This data indicates that ER recruitment of Far11
by Far9 requires the Far3-7-8 subcomplex.
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Figure 5. Interaction between Far9 and Far11 is greatly reduced in the absence of Far3,
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(A) Cell lysates of strains TPY1411 (WT), TPY1412 (far3Δ), TPY1413 (far7Δ), and
TPY1416 (far8Δ) coexpressing Far9-myc and Far11-HA (pZL2762) and the strain SY4064
(WT) expressing Far11-HA alone were subjected to immunoprecipitation with anti-myc
antibody. HA- and myc-tagged proteins were detected by immunoblotting. An asterisk
denotes a proteolytic product of Far11-HA (93).
(B) Model depicting interaction between Far11 and Far9 in wildtype versus far3Δ far7Δ
or far8Δ mutants.
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3.4.6. ER localization of Far9 is required for its optimal function in TORC2
signaling
Yeast Far9 and Far10 and their human and fly orthologs all contain a tail-anchor
domain and a forkhead-associated (FHA) domain (Fig. 6A). Tail-anchored proteins
utilize the tail-anchor domain for membrane association (17). The finding that Far9 and
Far10 are able to localize to the ER in the absence of the other Far complex components
prompted us to determine the role of Far9’s tail-anchor in the ER localization of Far9.
Accordingly, I constructed a GFP-tagged C-terminal truncation mutant of Far9, GFPFar9ΔC and examined its location in far9Δ mutant cells. Unlike GFP-tagged wild-type
Far9, GFP-Far9ΔC localized diffusely in the cytoplasm (Fig. 6B), indicating that the tailanchor domain of Far9 is required for its ER localization.

Recently, I proposed that the Far complex antagonizes TORC2 signaling by
showing that a far9Δ mutation or loss of other Far complex components are able to
bypass a tor2 temperature sensitive (tor2-21) mutation (93). I sought to test whether ER
localization of the Far complex is required for its function. To that end, I introduced a
far9ΔC mutation, which results in the synthesis of Far9 without the tail-anchored
domain, at the genomic FAR9 locus in tor2-21 mutant cells. I then tested whether the
far9ΔC mutation could bypass the tor2-21 mutation and found that far9ΔC was able to
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partially mimic far9Δ in suppressing the growth defect of tor2-21 mutant cells grown at
36 °C and 37 °C (Fig. 6C). To exclude the possibility that the removal of the tail anchor
domain of Far9 may reduce the steady-state level of Far9 by reducing its stability, which
could explain the partial suppression of the tor2-21 growth defect at high temperatures,
I examined the levels of GFP-tagged Far9 and Far9ΔC in tor2-21 far9Δ cells and found
that Far9ΔC was expressed to similar levels as full length Far9 (Fig. 6D). Together these
data suggest that the suppression of the tor2-21 mutation by far9ΔC results from the loss
of ER localization of Far9 and that ER localization of Far9 is required for its optimal
function.
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Figure 6. The tail-anchor domain of Far9 is required for its ER localization.
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(A) Diagrammatic representations of Far9 and its orthologs in flies and humans. A
conserved FHA domain and the tail-anchor domain are indicated by gray and white
rectangles, respectively.
(B) ER Localization of Far9 requires the tail-anchor domain. far9Δ mutant cells
(TPY1048) expressing GFP-tagged Far9 (pTP179) or Far9ΔC (pTP554) were grown in SD
medium and observed by fluorescence microscopy.

(C) The tail-anchor domain of Far9 is required for the optimal function of Far9 in
TORC2 signaling. Serial dilutions of indicated cells (WT, SH100; tor2-21, SH121; tor2-21
far9Δ, TPY357; tor2-21 far9ΔC, TPY1341) were grown on YPD medium at 30 °C, 36 °C,
and 37 °C for 3-4 days.

(D) Loss of the tail-anchor domain of Far9 does not reduce its steady-state level. Total
cellular proteins of far9Δ mutant cells (TPY357) expressing GFP-Far9 or GFP-Far9ΔC
were prepared and separated by SDS-PAGE and GFP-tagged proteins were detected by
immunoblotting. 3-Phosphoglycerate kinase (Pgk1) was included as a loading control.
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3.5. Discussion
3.5.1. ER/nuclear envelope localization of STRIPAK complex components: a
universal theme
The Far complex is part of the yeast striatin interacting phosphatase and kinase
(STRIPAK) complex which is conserved in eukaryotes (14, 42, 48, 67, 93, 96). Cellular
localization of the Far complex proteins has been reported previously (9, 61, 76).
However, these studies report some inconsistent and conflicting results.

While

consistent with data from a genome-wide study on the localization of yeast proteins
and a study on cellular localization of tail-anchored proteins showing ER localization of
Far3, Far7, and Far8, and Far9, and Far10 (9, 61), this study provides a comprehensive
look into the localization of the Far Complex at the ER including the order of assembly
of the complex in an effort to rectify the discrepancies. Using fluorescence microscopy, I
found that functional Far-GFP fusions localize to the nuclear and plasma membrane
periphery indicative of endoplasmic reticulum localization. Co-localization of the FarGFP fusions with the ER packaging chaperone Shr3-RFP tagged protein confirm ER
localization of the Far complex. By systematically examining the localization of Far-GFP
fusions in sextuple far3/7/8/9/10/11Δ and various double farΔ mutant cells I determined
the order by which the Far complex organizes itself on the ER: Far9/10 establish a foot

108

hold on the ER utilizing the tail-anchor domain, and Far3/7/8 form a subcomplex that
bridges Far11 to Far9/10 at the ER (Fig. 7).

Inconsistencies in the localization of the Far proteins in the previous studies may
be explained by several possibilities. Cytoplasmic localization of Far9 in the genomewide study on yeast protein localization is most likely to be due to the tagging of GFP at
its C-terminus, which is expected to interfere with tail-anchor domain-dependent ER
membrane insertion of Far9. The clustering effect of Far10 in Beilharz et al.’s study may
result from a higher level of overexpression of Far10 from the relatively strong MET25
promoter than in my current study (78, 88). My data disagrees with Lisa-Sanatmaria et
al.’s study, which reported Far11 as a late-Golgi protein, Far3 as an early Golgi protein,
and Far9 on the transport vesicles between ER and the Golgi (76). Although these three
cellular compartments are all part of the protein secretion pathway downstream of ER,
proteins associated with these three compartments exhibit distinct cellular localization,
different from the ER (61, 82, 85). In Lisa-Sanatmaria et al.’s study, the authors added a
C-terminal CFP tag to Far9, failing to take into consideration the role of the tail-anchor
domain of Far9 on its cellular localization. Furthermore, the functionality of the fusion
proteins in the aforementioned study was not reported. If the investigators neglected to
confirm the functionality of their fusion proteins and were in fact not functional, this
could present another possibility that accounts for the localization differences. This
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study has comprehensively confirmed the functionality of the Far-GFP fusion proteins
for the analysis of their cellular localization, therefore my data showing ER localization
of the Far complex should lie to rest the dispute over which cellular compartment the
Far complex is associated with in yeast.

ER/nuclear envelope localization of proteins associated with the STRIPAK
complex seems to be a conserved feature. S. cerevisiae Far9/10 and their orthologs all
contain a tail anchor domain at the extreme C-terminus (Fig. 6A and data not shown).
The human ortholog of yeast Far9/10, SLMAP, has been shown to associate with the ER
and nuclear envelope (21, 42). Two components of the STRIPAK complex in the fission
yeast S. pombe, Csc2 (S. cerevisiae Far11 ortholog) and Csc3 (S. cerevisiae Far8 ortholog)
also associate with the nuclear envelope/ER. Csc1, a component of the S. pombe
STRIPAK complex and the S. cerevisiae Far9/10 ortholog, was not found to localize to the
nuclear envelope (109). However, this could be due to the addition of GFP at its Cterminus, which includes a tail-anchor domain. A C-terminal GFP tag is expected to
interfere with membrane insertion of tail-anchor domain proteins. ER localization of the
STRIPAK components appears to be important for their function: In muscle cells,
SLMAP is associated with the sarcolemmal membrane, which is derived from the ER
and important for muscle cell function (51, 53, 89). Here I show that ER localization of
the Far complex is required for its optimal function in TORC2 signaling. How is ER
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localization of the yeast Far complex required for its function in TORC2 signaling?
Previously, I have shown that the yeast Far complex and PP2A negatively regulate
TORC2 signaling by promoting dephosphorylation of the TORC2 substrate Slm1 and
possibly Slm2, Ypk1 and Ypk2, all of which associate with the plasma membrane (37,
90). The association with the Far complex could bring PP2A to the periplasmic region to
facilitate dephosphorylation of TORC2 substrates (Fig.8).

Unlike S. cerevisiae Far proteins, human SLMAP and the S. pombe STRIPAK
complex also localize to the centrosome and the spindle pole body respectively (42, 52,
109). Consistent with their localization in the centrosome/spindle pole body, the human
and S. pombe STRIPAK complexes have been proposed to play roles in mitosis (42, 52,
109). Failure to detect localization of the yeast Far complex components and even the
Far9 truncation mutant without its tail-anchor domain to the spindle pole body is
consistent with Frost et al.’s hypothesis that the function of STRIPAK complex may
have been “repurposed” and the S. cerevisiae STRIPAK complex has lost its function in
mitosis (42).
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3.5.2. ER localization of the yeast Far complex has a role in TORC2 signaling
Previously, I reported that mutations in the Far complex suppresses TORC2
deficiency in the order: far11Δ > far8/9Δ > far3/7Δ > far10Δ (93). It is interesting to note
that Far11, which is the most peripheral component of the complex according to this
study, is also the most important among the six Far proteins in TORC2 signaling.
Although this result is surprising, it may help understand why ER localization of the
Far complex is not absolutely required for its function in TORC2 signaling. Far3 and
Far7 are able to form a complex in the absence of the other four Far proteins.
Coincidently, mutant effects of far3Δ and far7Δ on TORC2 signaling are most similar,
suggesting that their roles in the Far complex are equal. Far3 and Far7 are only found in
a restricted set of fungal species and lack apparent orthologs in animals (42). However,
yeast Far3/Far7 and human SIKE/FGFR1OP2 are all relatively small proteins predicted
to have a coiled-coil domain (49, 68, 73), suggesting that Far3/Far7 may be the
functional or structural counterparts of human SIKE/FGFR1OP2. Interestingly, the
STRIPAK complex in S. pombe contains a novel protein of 166 residues, Csc4, which is
also predicted to have a coiled-coil domain (109). It is possible that these small, coiledcoil domain proteins may play the same structural role in the STRIPAK complex in
different species as a result of divergent evolution.
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In this report, I found that Far3, Far7, and Far8 are able to form a subcomplex
independently of Far9, Far10, and Far11. Far8 shares limited sequence homology to
striatins, which are the B’’’ regulatory subunits of PP2A phosphatase. The PP2A
holoenzyme in yeast is a heterotrimer consisting of the scaffolding A subunit Tpd3, the
regulatory B subunit Cdc55 or B’ subunit Rts1, and one of the two homologous and
functionally redundant catalytic C subunits, Pph21 or Pph22 (34). It is not clear whether
Far8 is a B type regulatory subunit of PP2A due to my previous finding that an rts1
mutation has a similar phenotype as mutations in the Far complex components in
TORC2 signaling. Human Striatin 3 and its Sordaria Macrospora ortholog PRO11 have
been reported to contain an N-terminal coiled-coil region and both proteins are critical
components in the organization of the respective STRIPAK complexes (14, 67). Like
human striatins, yeast Far8 was also predicted to contain an N-terminal coiled-coil
domain (68, 73). Interestingly, almost all components of the Far complex are predicted
to contain coiled-coil domains (68, 73). These coiled-coil domains may mediate proteinprotein interactions and provide a structural framework for the organization of the Far
complex. Further research will be conducted to uncover the role of Far8 in the yeast
STRIPAK complex and how the Far complex interfaces with PP2A.

114

TORC2

Plasma Mem
br

N

HEAT

Tor2 FAT

Kinase

P

C

ane

P P

SLM1

Avo1

Avo3
Bit61

FRB

Lst8
P
P

Avo2

Far8

r3
Fa

Far11

Organization of the actin
cytoskeleton / Cell Wall Synthesis

Fa
r7

Rts1
Pph21/22
3
Tpd

Far10

Far9

Endoplasmic

Figure 8. Model of PP2A-Far complex’s role in TORC2 signaling in vivo.

115

Reticulum

Table 2. S. cerevisiae strains used in Chapter 3.
Strain

Genotype

Source Application

SY2227 (WT)

MATa ade1-1 leu2-2,113 trp1 ura3-52 bar1
HIS3::pFUS1::HIS3 mfa2-1::FUS1-lacZ
rad16::pGAL1::STE4

(68)

TPY1010 (far3)

SY2227 far3::kanMX4

This
study

Fig. 1A,
3A

TPY1013 (far7)

SY2227 far7::kanMX4

This
study

Fig. 1A,
3B

TPY1015 (far8)

SY2227 far8::kanMX4

This
study

Fig. 1A,
3C

TPY1048 (far9)

SY2227 far9::kanMX4

This
study

Fig. 1A,
6B

TPY1072 (far10) SY2227 far10::kanMX4

This
study

Fig. 1A

SY4064 (far11)

SY2227 far11::kanMX4

(68)

Fig. 1A,
3D, 5

SH100 (WT)

MATa leu2-3,112 ura3-52 rme1 trp1 his4
HMLa ade2 tor2::ADE2 [YCplac111::TOR2]

(57)

Fig. 6C

SH121 (tor2-21)

MATa leu2-3,112 ura3-52 rme1 trp1 his4
HMLa ade2 tor2::ADE2 [YCplac111::tor2-21]

(57)

Fig. 6C

TPY157 (tor2-21 SH121 far3::kanMX4
far3)

(93)

Fig. 1B

TPY147 (tor2-21 SH121 far7::kanMX4
far7)

(93)

Fig. 1B

TPY213 (tor2-21 SH121 far8::kanMX4
far8)

(93)

Fig. 1B

TPY357 (tor2-21 SH121 far9::kanMX4
far9)

(93)

Fig. 1B,
6C-D

TPY151 (tor2-21 SH121 far10::kanMX4
far10)

(93)

Fig. 1B

TPY116 (tor2-21 SH121 far11::kanMX4
far11)

(93)

Fig. 1B
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SY4075 (far
sext)

SY2227 far3::LEU2 far7::CgTRP1 far8::URA3
far9::HYGB far10::KAN far11::NAT

(68)

TPY845 (far
sext ura3)

SY4075 ura3::kanMX4

This
study

Fig. 2, 4A,
4C

TPY1358 (far3
far7)

SY2227 far3::kanMX4 far7::TRP1 [pRS416FAR3-GFP]

This
study

Fig. 3A

TPY1361 (far3
far8)

SY2227 far3::kanMX4 far8::TRP1 [pRS416FAR3-GFP]

This
study

Fig. 3A

TPY1348 (far3
far9)

SY2227 far3::kanMX4 far9::TRP1 [pRS416FAR3-GFP]

This
study

Fig. 3A

TPY1363 (far3
far10)

SY2227 far3::kanMX4 far10::TRP1 [pRS416FAR3-GFP]

This
study

Fig. 3A

TPY1402 (far3
far11)

SY2227 far3::kanMX4 far11::TRP1 [pRS416FAR3-GFP]

This
study

Fig. 3A

TPY1408 (far7
far3)

SY2227 far7::kanMX4 far3::TRP1 [pRS416FAR7-GFP]

This
study

Fig. 3B

TPY1366 (far7
far8)

SY2227 far7::kanMX4 far8::TRP1 [pRS416FAR7-GFP]

This
study

Fig. 3B

TPY1350 (far7
far9)

SY2227 far7::kanMX4 far9::TRP1 [pRS416FAR7-GFP]

This
study

Fig. 3B

TPY1368 (far7
far10)

SY2227 far7::kanMX4 far10::TRP1 [pRS416FAR7-GFP]

This
study

Fig. 3B

TPY1352 (far7
far11)

SY2227 far7::kanMX4 far11::TRP1 [pRS416FAR7-GFP]

This
study

Fig. 3B

TPY1369 (far8
far3)

SY2227 far8::kanMX4 far3::TRP1 [pRS416FAR8-GFP]

This
study

Fig. 3C,
4B

TPY1370 (far8
far7)

SY2227 far8::kanMX4 far7::TRP1 [pRS416FAR8-GFP]

This
study

Fig. 3C,
4B

TPY1351 (far8
far9)

SY2227 far8::kanMX4 far9::TRP1 [pRS416FAR8-GFP]

This
study

Fig. 3C

TPY1373 (far8
far10)

SY2227 far8::kanMX4 far10::TRP1 [pRS416FAR8-GFP]

This
study

Fig. 3C

TPY1405 (far8
far11)

SY2227 far8::kanMX4 far11::TRP1 [pRS416FAR8-GFP]

This
study

Fig. 3C
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TPY1374 (far11
far3)

SY2227 far11::kanMX4 far3::TRP1 [pRS416MKS1-FAR11-GFP]

This
study

Fig. 3D

TPY1377 (far11
far7)

SY2227 far11::kanMX4 far7::TRP1 [pRS416MKS1-FAR11-GFP]

This
study

Fig. 3D

TPY1406 (far11
far8)

SY2227 far11::kanMX4 far8::TRP1 [pRS416MKS1-FAR11-GFP]

This
study

Fig. 3D

TPY1410 (far11
far9)

SY2227 far11::kanMX4 far9::TRP1 [pRS416MKS1-FAR11-GFP]

This
study

Fig. 3D

TPY1379 (far11
far10)

SY2227 far11::kanMX4 far10::TRP1 [pRS416- This
MKS1-FAR11-GFP]
study

Fig. 3D

SY4080 (FAR9myc)

SY2227 FAR9-MYC13-KAN [pSL2771, CEN
LEU2]

(68)

TPY1411
(FAR9-myc)

SY4080 without the pSL2771 plasmid

This
study

SY4070 (FAR9myc far3)

SY2227 far3::LEU2 FAR9-MYC13-KAN
[pSL2784, 2µ URA3 FAR3-HA]

(68)

TPY1412 (far3
FAR9-myc)

SY4070 without the pSL2784 plasmid

This
study

Fig. 5

TPY1413 (far7
FAR9-myc)

TPY1411 far7::TRP1

This
study

Fig. 5

TPY1416 (far8
FAR9-myc)

TPY1411 far8::TRP1

This
study

Fig. 5

TPY1341
(far9ΔC)

SH121 far9ΔC

This
study

Fig. 6C

Fig. 5

Table 3. Plasmids used in Chapter 3
Plasmid

Description

Source Application

pTP201

pRS414-SHR3-RFP expressing Shr3 from its own
promoter with an RFP tag at the C-terminus.

This
study

Fig. 1B

pTP143

pRS416-FAR3-GFP, expressing Far3 from its own

This

Fig. 1A-B,
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promoter with a GFP tag at the C-terminus.

study

2, 3A, 4A

pTP164

pRS416-FAR7-GFP, expressing Far7 from its own
promoter with a GFP tag at the C-terminus.

This
study

Fig. 1A-B,
2, 3B, 4A

pTP131

pRS416-FAR8-GFP, expressing Far8 from its own
promoter with a GFP tag at the C-terminus.

This
study

Fig. 1A-B,
2, 3C, 4B

pTP179

pRS416-MKS1-GFP-FAR9, expressing Far9 from the
MKS1 promoter with a GFP tag at the N-terminus.

This
study

Fig. 1A-B,
2, 6B, 6D

pTP203

pRS416-MKS1-GFP-FAR10, expressing Far10 from the
MKS1 promoter with a GFP tag at the N-terminus.

This
study

Fig. 1A-B,
2

pZL2564 pRS416-FAR11-GFP, expressing Far11 from its own
promoter with a GFP tag at the C-terminus.

This
study

Fig. 1A-B,
2, 3D

pTP646

pRS418-FAR7-HA, expressing Far7 from its own
promoter with a 3xHA tag at the C-terminus.

This
study

Fig. 4A-C

pTP658

pRS418-FAR8-HA, expressing Far8 from its own
promoter with a 3xHA tag at the C-terminus.

This
study

Fig. 4A

pTP655

pRS418-FAR3-HA, expressing Far3 from its own
promoter with a 3xHA tag at the C-terminus.

This
study

Fig. 4A-C

pTP664

pRS418-FAR7-FAR3-HA, expressing non-tagged Far7
from its own promoter and Far3 from its own promoter
with a 3xHA tag at the C-terminus.

This
study

Fig. 4C

pTP673

pRS418-FAR3-FAR7-HA, expressing non-tagged Far3
from its own promoter and Far7 from its own promoter
with a 3xHA tag at the C-terminus.

This
study

Fig. 4C

pZL2762 pRS416-FAR11-HA, expressing Far11 from its own
promoter with a 3xHA tag at the C-terminus.

(93)

Fig. 5

pTP554

This
study

Fig. 6B,
6D

pRS416-MKS1p-GFP-FAR9ΔC, expressing Far9ΔC from
the MKS1 promoter with a GFP tag at the N-terminus.
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APPENDIX
tor1Δ
tor1Δ tor2-21
tor2-21
far11Δ
tor1Δ
tor2-21
WT
sac7Δ
30°C

37°C

Figure A1. sac7Δ and far11Δ do not suppress the temperature sensitive growth
phenotype of a tor1Δtor2-21 double mutant.
Wild-type (SH100), tor1Δ tor2-21 (SH221), tor1Δ tor2-21 sac7Δ (TPY112), and tor1Δ tor2-21
far11Δ (TPY118) cells were grown on YPD plates at 30 °C and 37 °C.
fpr1Δ
WT
sac7Δ
far11Δ

0 nM rapamycin

2 nM rapamycin

3 nM rapamycin

5 nM rapamycin

7 nM rapamycin

10 nM rapamycin

15 nM rapamycin

20 nM rapamycin

fpr1Δ
WT
sac7Δ
far11Δ

Figure A2. The effect of rapamycin on the growth of sac7Δ and far11Δ mutant cells.
Cultures of wild-type (ZLY423), fpr1Δ (TPY122), sac7Δ (ZLY2404), and far11Δ mutant
(TPY114) cells were serially diluted and spotted on YPD plates supplemented with
different concentrations of rapamycin.
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Vector

FAR11-HA

far11Δ

Figure A3. A FAR11-HA fusion construct is functional.
far11Δ mutant cells (lst8Δ ade2-1 far11Δ, TPY114) carrying plasmid pRS412-LST8 and
either pRS416 empty vector (Vector) or pRS416-FAR11-HA (FAR11-HA, pZL2762) were

kD
230

Protein Size
Ladder

grown on YNBcasD medium supplemented with adenine.
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Figure A4. Far11-HA in total cellular proteins prepared by trichloroacetic acid
precipitation exists as a single band on Western blots.
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Total cellular proteins were prepared from the yeast strain SY4078 carrying a
centromeric plasmid encoding FAR11-HA (pZL2762) using the NaOH-β
mercaptoethanol-trichloroacetic acid method as described (129) and separated by SDSPAGE. Far11-HA was detected by immunoblotting with the high affinity rat
monoclonal anti-HA antibody 3F10 (Roche).

30°C

37°C

WT
tor2-21
tor2-21 far9Δ
tor2-21 far10Δ
tor2-21 far9Δ far10Δ

Figure A5. The effect of far9Δ and far10Δ on suppressing the temperature-sensitive
growth phenotype of a tor2-21 mutant.
Wild-type (SH100), tor2-21 (SH121), tor2-21 far9Δ (TPY207), tor2-21 far10Δ (TPY264) and
tor2-21 far9Δ far10Δ mutant (TPY220) cells were serially diluted and spotted on YPD
plates and grown at 30 °C and 37 °C.
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MATa far11::HIS3 tor2::kanMX4
MATα FAR11
TOR2

MATa far11::HIS3 avo1::kanMX4
MATα FAR11
AVO1

MATa far11::HIS3 avo3::kanMX4
MATα FAR11
AVO3

Figure A6. Tetrad analysis of sporulated diploid cells heterozygous for mutations in
FAR11 and TOR2, AVO1, or AVO3.
None of the colonies were geneticin (G418) resistant, indicating that no viable tor2Δ,
avo1Δ, or avo3Δ mutant haploid cells were generated.
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A

tpd3Δ + vector

WT
+ vector

B

tpd3Δ
+pTPD3-myc

pph21/22Δ
+ vector
WT
+ vector

pph21/22Δ
+ pPPH21-myc

Figure A7. Tpd3-myc and Pph21-myc are functional.
(A) Wild type (BY4741) and isogenic tpd3Δ mutant (BY4741 tpd3) cells carrying an
empty vector (pRS415) or TPD3-myc plasmid (pTP242) as indicated were grown on
leucine-dropout medium and the picture was taken after 3 days.
(B) Wild type (BY4741) and isogenic pph21/22Δ mutant (BY4741 pph21/22) cells carrying
an empty vector (pRS415) or PPH21-myc plasmid (pTP244) were analyzed for cell
growth as described for panel A.
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Figure A8. Immunoblot analysis of HA-tagged Ypk2 (A) and Slm2 (B).

Wild-type (WT, SH100) and temperature-sensitive tor2-21 mutant cells (SH121)
expressing C-terminal 3xHA-tagged Ypk2 or Slm2 from a centromeric plasmid (YPK2HA, pTP271; SLM2-HA, pTP377) were grown in YNBcasD medium at 30 °C to mid-log
phase and switched to 37 °C for 3h before cellular proteins were processed for Western
blotting.
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Table 1. Supplemental Strains used in Chapter 2.
Strain
TPY114 (far11)

SY4078
SH100 (WT)

SH121 (tor221)
SH221 (tor1
tor2-21)
TPY110 (tor221 sac7)
TPY311 (tor221 far11)
TPY301 (tor221 sac7 far11)
TPY112
TPY118
TPY207 (tor221 far9)
TPY264 (tor221 far10)
TPY220 (tor221 far9 far10)
ZLY423 (WT)
TPY122 (fpr1)

ZLY2404
(sac7)
TPY114 (far11)

Genotype
MATa ade2-1 ura3 his3-11,15 leu2
lst8::LEU2 far11::kanMX4 [pRS412LST8]
SY2227 FAR7-myc13-KAN
<pSL2771>
MATa leu2-3,112 ura3-52 rme1 trp1
his4 HMLa ade2 tor2::ADE2
[YCplac111::TOR2]
MATa leu2-3,112 ura3-52 rme1 trp1
his4 HMLa ade2 tor2::ADE2
[YCplac111::tor2-21]
MATa leu2-3,112 ura3-52 rme1 trp1
his3 HMLa ade2 tor1::HIS3
tor2::ADE2 [YCplac111::tor2-21]
SH121 sac7::kanMX4

Source
This study

Application
Fig, A2, A3

(68)

Fig. A4

(57)

Fig. A1, A5,
A8

SH121 far11::TRP1

This study

SH121 sac7::kanMX4 far11::TRP1

This study

SH221 sac7::kanMX4
SH221 far11::kanMX4
SH121 far9::kanMX4

This study
This study
This study

Fig. A1
Fig. A1
Fig. A5

SH121 far10::URA3

This study

Fig. A5

SH121 far9::kanMX4 far10::URA3

This study

Fig. A5

MATa ade2-1 ura3 his3-11,15 leu2
lst8::LEU2 [pRS412-LST8]
MATa ade2-1 ura3 his3-11,15 leu2
lst8::LEU2 fpr1::kanMX4 [pRS412LST8]
MATa ade2-1 ura3 his3-11,15 leu2
lst8::LEU2 sac7::kanMX4 [pRS412LST8]
MATa ade2-1 ura3 his3-11,15 leu2
lst8::LEU2 far11::kanMX4 [pRS412LST8]

This study.

Fig. A2

This study

Fig. A2

This study

Fig. A2
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Fig. A5, A8

Fig. A1

This study

This study

BY4741
(pph21/22)
BY4741
BY4741 tpd3
BY4743
BY4743
tor2/TOR2
BY4743
avo1/AVO1
BY4743
avo3/AVO3
TPY654
TPY652
TPY653

MATa ura3 leu2 his3 met15
pph21::kanMX4 pph22::kanMX4
MATa ura3 leu2 his3 met15
BY4741 tpd3::kanMX4
MATa/MATalpha ura3/ura3 leu2/leu2
his3/his3 lys2/LYS2 met15/MET15
BY4743 tor2::kanMX4/TOR2

This study
Yeast
genome
deletion
project

Fig. A7
Fig. A7
Fig. A7

BY4743 avo1::kanMX4/AVO1
BY4743 avo3::kanMX4/AVO3
BY4743 tor2::kanMX4/TOR2
far11::HIS3/FAR11
BY4743 avo1::kanMX4/AVO1
far11::HIS3/FAR11
BY4743 avo3::kanMX4/AVO3
far11::HIS3/FAR11

This study

Fig. A6

This study

Fig. A6

This study

Fig. A6

Table 2. Supplemental Plasmids used in Chapter 2.
Plasmid Description
pZL2762 pRS416-FAR11-HA, expressing Far11 from its own
promoter with a 3xHA tag at the C-terminus.
pTP377 pRS416-SLM2-HA, expressing Slm2 from its own promoter
with a 3xHA tag at the C-terminus.
pTP271 pRS416-YPK2-HA, expressing Ypk2 from its own promoter
with a 3xHA tag at the C-terminus.
pZL1255 pRS412-LST8
pTP242 pRS415-ADH1-TPD3-myc, expressing Tpd3 from the
ADH1 promoter with a 3xmyc tag at the C-terminus.
pTP244 pRS415-PPH21-myc, expressing Pph21 from its own
promoter with a 3xmyc tag at the C-terminus.

152

Source
This study
This study
This study
This study
This study
This study
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